2024-12-15 21:56:34,148 - graphrag.config.read_dotenv - INFO - Loading pipeline .env file
‚†ã GraphRAG Indexer 2024-12-15 21:56:34,158 - __main__ - INFO - Starting build_index with run_id=20241215-215634
Starting build_index with run_id=20241215-215634
‚†ã GraphRAG Indexer 2024-12-15 21:56:34,180 - graphrag.index.create_pipeline_config - INFO - skipping workflows 
2024-12-15 21:56:34,190 - graphrag.index.run.run - INFO - Running pipeline
2024-12-15 21:56:34,191 - graphrag.storage.file_pipeline_storage - INFO - Creating file storage at /Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/plugins/dev/graphrag/python-lib/graphrag/test/output
2024-12-15 21:56:34,191 - graphrag.index.input.factory - INFO - loading input from root_dir=input
2024-12-15 21:56:34,191 - graphrag.index.input.factory - INFO - using file storage for input
‚†ã GraphRAG Indexer 2024-12-15 21:56:34,192 - graphrag.storage.file_pipeline_storage - INFO - search /Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/plugins/dev/graphrag/python-lib/graphrag/test/input for files matching .*\.txt$
2024-12-15 21:56:34,193 - graphrag.index.input.text - INFO - found text files from input, found [('ctgov_fullcontent_1.txt', {})]
2024-12-15 21:56:34,200 - graphrag.index.input.text - INFO - Found 1 files, loading 1
2024-12-15 21:56:34,202 - graphrag.index.workflows.load - INFO - Workflow Run Order: ['create_base_text_units', 'create_final_documents', 'extract_graph', 'compute_communities', 'create_final_entities', 'create_final_relationships', 'create_final_communities', 'create_final_nodes', 'create_final_text_units', 'create_final_community_reports', 'generate_text_embeddings']
2024-12-15 21:56:34,202 - graphrag.index.run.run - INFO - Final # of rows loaded: 1
2024-12-15 21:56:34,296 - graphrag.index.run.workflow - INFO - dependencies for create_base_text_units: []
‚†ô GraphRAG Indexer 
üöÄ create_base_text_units
Empty DataFrame
Columns: []
Index: []
‚†ß GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†á GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ create_final_documents
                                                  id  human_readable_id                    title                                               text                                      text_unit_ids
0  3e483c6a024c09ea2f5d53d99bb05cc1da5c58382ecb1d...                  1  ctgov_fullcontent_1.txt  # NCTId\nNCT06273124\n# study_url\nhttps://www...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
‚†è GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†è GraphRAG Indexer 
 *************** index/graph/extractors/graph/graph_extractor.py: calling LLM
 *************** index/graph/extractors/graph/graph_extractor.py: calling LLM
 *************** index/graph/extractors/graph/graph_extractor.py: calling LLM
‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îî‚îÄ‚îÄ extract_graph
    ‚îî‚îÄ‚îÄ Verb extract_graph ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ   0% -:--:-- 0:00:002024-12-15 21:56:40,025 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,025 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={}
2024-12-15 21:56:40,025 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: ("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is the lead sponsor of the study investigating an extended wear insulin infusion set for people with Type 1 Diabetes.)
##
("entity"<|>JAEB CENTER FOR HEALTH RESEARCH<|>ORGANIZATION<|>Jaeb Center for Health Research is a collaborator in the study.)
##
("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director at Capillary Biomedical for the insulin infusion set study.)
##
("entity"<|>JOHN C REED<|>PERSON<|>John C Reed is the principal investigator at Endocrine Research Solutions in Roswell, Georgia, for the study.)
##
("entity"<|>DAVIDA KRUGER<|>PERSON<|>Davida Kruger is a principal investigator at Henry Ford Health System in Detroit, Michigan, for the study.)
##
("entity"<|>BRITTANY DENNIS<|>PERSON<|>Brittany Dennis is a contact for Hoag Memorial Hospital Presbyterian in Newport Beach, California, for the study.)
##
("entity"<|>RICHARD BERGENSTAL<|>PERSON<|>Richard Bergenstal is a principal investigator at International Diabetes Center - HealthPartners Institute in Minneapolis, Minnesota, for the study.)
##
("entity"<|>SAMANTHA LANGE<|>PERSON<|>Samantha Lange is a contact for Barbara Davis Center in Aurora, Colorado, for the study.)
##
("entity"<|>GRAZIA ALEPPO<|>PERSON<|>Grazia Aleppo is a principal investigator at Northwestern University in Evanston, Illinois, for the study.)
##
("entity"<|>WYATT LARSON<|>PERSON<|>Wyatt Larson is a contact for Rocky Mountain Clinical Research in Idaho Falls, Idaho, for the study.)
##
("entity"<|>JEAN CHEN<|>PERSON<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology in Austin, Texas, for the study.)
##
("entity"<|>TINA MITCHELL<|>PERSON<|>Tina Mitchell is a contact for Rainier Clinical Research Center in Renton, Washington, for the study.)
##
("entity"<|>RAYHAN LAL<|>PERSON<|>Rayhan Lal is a principal investigator at Stanford University in Stanford, California, for the study.)
##
("entity"<|>DORI KHAKPOUR<|>PERSON<|>Dori Khakpour is a contact for University of Washington in Seattle, Washington, for the study.)
##
("entity"<|>CAMILLA LEVISTER<|>PERSON<|>Camilla Levister is a principal investigator at Icahn School of Medicine at Mt. Sinai in New York, New York, for the study.)
##
("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is involved in the study but is not yet recruiting participants.)
##
("entity"<|>EXTENDED WEAR INSULIN INFUSION SET<|>EVENT<|>The Extended Wear Insulin Infusion Set (EWIS) is the subject of the investigational study aimed at assessing its use in people with Type 1 Diabetes.)
##
("relationship"<|>TANDEM DIABETES CARE, INC.<|>EXTENDED WEAR INSULIN INFUSION SET<|>Tandem Diabetes Care, Inc. is the lead sponsor of the study investigating the Extended Wear Insulin Infusion Set<|>9)
##
("relationship"<|>JAEB CENTER FOR HEALTH RESEARCH<|>EXTENDED WEAR INSULIN INFUSION SET<|>Jaeb Center for Health Research collaborates on the study of the Extended Wear Insulin Infusion Set<|>5)
##
("relationship"<|>ALAYNE LEHMAN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Alayne Lehman is the study director for the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>JOHN C REED<|>EXTENDED WEAR INSULIN INFUSION SET<|>John C Reed is the principal investigator for the Extended Wear Insulin Infusion Set study at Endocrine Research Solutions<|>8)
##
("relationship"<|>DAVIDA KRUGER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Davida Kruger is a principal investigator for the Extended Wear Insulin Infusion Set study at Henry Ford Health System<|>8)
##
("relationship"<|>BRITTANY DENNIS<|>EXTENDED WEAR INSULIN INFUSION SET<|>Brittany Dennis is a contact for the Extended Wear Insulin Infusion Set study at Hoag Memorial Hospital Presbyterian<|>5)
##
("relationship"<|>RICHARD BERGENSTAL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Richard Bergenstal is a principal investigator for the Extended Wear Insulin Infusion Set study at International Diabetes Center<|>8)
##
("relationship"<|>SAMANTHA LANGE<|>EXTENDED WEAR INSULIN INFUSION SET<|>Samantha Lange is a contact for the Extended Wear Insulin Infusion Set study at Barbara Davis Center<|>5)
##
("relationship"<|>GRAZIA ALEPPO<|>EXTENDED WEAR INSULIN INFUSION SET<|>Grazia Aleppo is a principal investigator for the Extended Wear Insulin Infusion Set study at Northwestern University<|>8)
##
("relationship"<|>WYATT LARSON<|>EXTENDED WEAR INSULIN INFUSION SET<|>Wyatt Larson is a contact for the Extended Wear Insulin Infusion Set study at Rocky Mountain Clinical Research<|>5)
##
("relationship"<|>JEAN CHEN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Jean Chen is a principal investigator for the Extended Wear Insulin Infusion Set study at Texas Diabetes and Endocrinology<|>8)
##
("relationship"<|>TINA MITCHELL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Tina Mitchell is a contact for the Extended Wear Insulin Infusion Set study at Rainier Clinical Research Center<|>5)
##
("relationship"<|>RAYHAN LAL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Rayhan Lal is a principal investigator for the Extended Wear Insulin Infusion Set study at Stanford University<|>8)
##
("relationship"<|>DORI KHAKPOUR<|>EXTENDED WEAR INSULIN INFUSION SET<|>Dori Khakpour is a contact for the Extended Wear Insulin Infusion Set study at University of Washington<|>5)
##
("relationship"<|>CAMILLA LEVISTER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Camilla Levister is a principal investigator for the Extended Wear Insulin Infusion Set study at Icahn School of Medicine<|>8)
##
 *************** index/graph/extractors/graph/graph_extractor.py: for i in range, calling LLM
‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îî‚îÄ‚îÄ extract_graph
    ‚îî‚îÄ‚îÄ Verb extract_graph ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ   0% -:--:-- 0:00:002024-12-15 21:56:40,031 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,031 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={}
2024-12-15 21:56:40,031 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: ("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a medical school located in New York, involved in various research studies and clinical trials.)
##
("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a renowned medical center in Rochester, Minnesota, known for its clinical research and patient care.)
##
("entity"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>ORGANIZATION<|>SUNY Upstate Medical University is a public medical university in Syracuse, New York, engaged in medical education and research.)
##
("entity"<|>MASSACHUSETTS GENERAL HOSPITAL<|>ORGANIZATION<|>Massachusetts General Hospital is a major teaching hospital in Boston, Massachusetts, involved in clinical research and patient care.)
##
("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is a company that develops innovative insulin delivery products for people with diabetes.)
##
("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is a registered nurse and the study director for a clinical trial related to Type 1 diabetes at Capillary Biomedical.)
##
("entity"<|>YOGISH KUDVA<|>PERSON<|>Yogish Kudva is a medical doctor and principal investigator at Mayo Clinic, involved in diabetes research.)
##
("entity"<|>SUZAN BZDICK<|>PERSON<|>Suzan Bzdick is a registered nurse and contact person for the study at SUNY Upstate Medical University.)
##
("entity"<|>RUTH WEINSTOCK<|>PERSON<|>Ruth Weinstock is a medical doctor and principal investigator at SUNY Upstate Medical University, focusing on diabetes research.)
##
("entity"<|>COREY KUREK<|>PERSON<|>Corey Kurek is a contact person at Mayo Clinic for the clinical trial.)
##
("entity"<|>MELISSA PUTMAN<|>PERSON<|>Melissa Putman is a medical doctor and principal investigator at Massachusetts General Hospital.)
##
("entity"<|>AMY SABEAN<|>PERSON<|>Amy Sabean is a contact person at Massachusetts General Hospital for the clinical trial.)
##
("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin, requiring ongoing management and research for treatment options.)
##
("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is the study director for a clinical trial sponsored by Tandem Diabetes Care, Inc.<|>8)
##
("relationship"<|>YOGISH KUDVA<|>MAYO CLINIC<|>Yogish Kudva is a principal investigator at Mayo Clinic, which is involved in diabetes research.<|>7)
##
("relationship"<|>SUZAN BZDICK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Suzan Bzdick is a contact person for the study at SUNY Upstate Medical University, which is conducting diabetes research.<|>7)
##
("relationship"<|>RUTH WEINSTOCK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on diabetes research.<|>7)
##
("relationship"<|>COREY KUREK<|>MAYO CLINIC<|>Corey Kurek is a contact person for the clinical trial at Mayo Clinic.<|>6)
##
("relationship"<|>MELISSA PUTMAN<|>MASSACHUSETTS GENERAL HOSPITAL<|>Melissa Putman is a principal investigator at Massachusetts General Hospital, which is involved in diabetes research.<|>7)
##
("relationship"<|>AMY SABEAN<|>MASSACHUSETTS GENERAL HOSPITAL<|>Amy Sabean is a contact person for the clinical trial at Massachusetts General Hospital.<|>6)
##
("relationship"<|>TYPE 1 DIABETES<|>TANDEM DIABETES CARE, INC.<|>Tandem Diabetes Care, Inc. is sponsoring a clinical trial related to Type 1 diabetes.<|>9)
##
("relationship"<|>TYPE 1 DIABETES<|>YOGISH KUDVA<|>Yogish Kudva is involved in research related to Type 1 diabetes at Mayo Clinic.<|>8)
##
("relationship"<|>TYPE 1 DIABETES<|>RUTH WEINSTOCK<|>Ruth Weinstock is conducting research on Type 1 diabetes at SUNY Upstate Medical University.<|>8)
##
 *************** index/graph/extractors/graph/graph_extractor.py: for i in range, calling LLM
‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îî‚îÄ‚îÄ extract_graph
    ‚îî‚îÄ‚îÄ Verb extract_graph ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ   0% -:--:-- 0:00:002024-12-15 21:56:40,036 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,036 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={}
2024-12-15 21:56:40,036 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: ("entity"<|>CAPILLARY BIOMEDICAL<|>ORGANIZATION<|>Capillary Biomedical is the organization conducting the clinical study involving an extended wear infusion set for adults with Type 1 diabetes.)
##
("entity"<|>TANDEM T:SLIM X2<|>ORGANIZATION<|>Tandem t:slim X2 is an insulin pump used in the study with Control-IQ technology and continuous Glucose Monitoring (CGM).)
##
("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 diabetes is the condition being studied in the clinical trial involving the extended wear infusion set.)
##
("entity"<|>UNITED STATES<|>GEO<|>The United States is the country where the clinical study will take place, enrolling participants from various locations.)
##
("entity"<|>START DATE<|>EVENT<|>The study is set to begin on March 7, 2024, marking the start of participant enrollment and data collection.)
##
("entity"<|>COMPLETION DATE<|>EVENT<|>The study is expected to be completed by January 15, 2025, concluding the data collection and analysis phase.)
##
("entity"<|>PARTICIPANTS<|>PERSON<|>Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers.)
##
("relationship"<|>CAPILLARY BIOMEDICAL<|>TANDEM T:SLIM X2<|>Capillary Biomedical is conducting a study that utilizes the Tandem t:slim X2 insulin pump for Type 1 diabetes management<|>8)
##
("relationship"<|>TYPE 1 DIABETES<|>CAPILLARY BIOMEDICAL<|>The study by Capillary Biomedical focuses on Type 1 diabetes and its management through an extended wear infusion set<|>9)
##
("relationship"<|>UNITED STATES<|>CAPILLARY BIOMEDICAL<|>The clinical study conducted by Capillary Biomedical will take place in the United States<|>7)
##
("relationship"<|>START DATE<|>CAPILLARY BIOMEDICAL<|>The study conducted by Capillary Biomedical is set to start on March 7, 2024<|>6)
##
("relationship"<|>COMPLETION DATE<|>CAPILLARY BIOMEDICAL<|>The study conducted by Capillary Biomedical is expected to be completed by January 15, 2025<|>6)
##
 *************** index/graph/extractors/graph/graph_extractor.py: for i in range, calling LLM
‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îî‚îÄ‚îÄ extract_graph
    ‚îî‚îÄ‚îÄ Verb extract_graph ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ   0% -:--:-- 0:00:002024-12-15 21:56:40,045 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,045 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'extract-continuation-0', 'history': [{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: # NCTId\nNCT06273124\n# study_url\nhttps://www.clinicaltrials.gov/study/NCT06273124\n# BriefTitle\nInvestigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes\n# OfficialTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n# OverallStatus\nRECRUITING\n# StartDate\n2024-03-07\n# PrimaryCompletionDate\n2025-01-15\n# CompletionDate\n2025-01-15\n# LeadSponsorName\nTandem Diabetes Care, Inc.\n# LeadSponsorClass\nINDUSTRY\n# BriefSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ‚â•250mg/dL for one hour\n# StudyType\nINTERVENTIONAL\n# Phase\n[\'NA\']\n# DesignAllocation\nNA\n# DesignInterventionModel\nSINGLE_GROUP\n# DesignPrimaryPurpose\nTREATMENT\n# DesignMasking\nNONE\n# EnrollmentCount\n260\n# EnrollmentType\nESTIMATED\n# HealthyVolunteers\nFalse\n# Sex\nALL\n# StdAge\n[\'ADULT\', \'OLDER_ADULT\']\n# collaborators\nJaeb Center for Health Research (OTHER)\n# officials\nAlayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)\n# clinical_site_contact\nEndocrine Research Solutions (RECRUITING), Roswell, Georgia, 30076, United States - John C Reed, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Jessica Tapia (CONTACT), 678-878-4750, jtapia.ers@gmail.com | Henry Ford Health System (NOT_YET_RECRUITING), Detroit, Michigan, 48202, United States - Davida Kruger, NP (PRINCIPAL_INVESTIGATOR), NA, NA | Davida Kruger (CONTACT), 313-916-3906, dkruger1@hfhs.org | Hoag Memorial Hospital Presbyterian (RECRUITING), Newport Beach, California, 92663, United States - Brittany Dennis (CONTACT), 949-764-6896, brittany.dennis@hoag.org | David Ahn, MD (PRINCIPAL_INVESTIGATOR), NA, NA | International Diabetes Center - HealthPartners Institute (NOT_YET_RECRUITING), Minneapolis, Minnesota, 55416, United States - Richard Bergenstal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Kathryn Leet, RD,LD, CDCES (CONTACT), 952-993-9793, kathryn.leet@parknicollet.com | Barbara Davis Center (NOT_YET_RECRUITING), Aurora, Colorado, 80045, United States - Samantha Lange (CONTACT), 303-724-7514, samantha.lange@cuanschutz.edu | Erin Cobry, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Northwestern University (NOT_YET_RECRUITING), Evanston, Illinois, 60208, United States - Grazia Aleppo, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Grazia Aleppo (CONTACT), 312-926-5431, aleppo@northwestern.edu | Rocky Mountain Clinical Research (NOT_YET_RECRUITING), Idaho Falls, Idaho, 83404, United States - Wyatt Larson (CONTACT), 208-525-3736, Wyatt.larson@idahomed.com | David Liljenquist, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Texas Diabetes and Endocrinology (NOT_YET_RECRUITING), Austin, Texas, 78731, United States - Jean Chen, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Emmanuel Lopez (CONTACT), 512-334-3505, elopez@texasdiabetes.com | Rainier Clinical Research Center (NOT_YET_RECRUITING), Renton, Washington, 98057, United States - Tina Mitchell (CONTACT), 425-251-1720, TMitchell@rainier-research.com | Frances Broyles, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Stanford University (NOT_YET_RECRUITING), Stanford, California, 94305, United States - Rayhan Lal (CONTACT), 925-727-1317, inforay@stanford.edu | Rayhan Lal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | University of Washington (NOT_YET_RECRUITING), Seattle, Washington, 98109, United States - Dori Khakpour (CONTACT), 206-945-4965, dorik@uw.edu | Irl Hirsch, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota,\n######################\nOutput:', 'role': 'user'}, {'role': 'assistant', 'content': '("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is the lead sponsor of the study investigating an extended wear insulin infusion set for people with Type 1 Diabetes.)\n##\n("entity"<|>JAEB CENTER FOR HEALTH RESEARCH<|>ORGANIZATION<|>Jaeb Center for Health Research is a collaborator in the study.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director at Capillary Biomedical for the insulin infusion set study.)\n##\n("entity"<|>JOHN C REED<|>PERSON<|>John C Reed is the principal investigator at Endocrine Research Solutions in Roswell, Georgia, for the study.)\n##\n("entity"<|>DAVIDA KRUGER<|>PERSON<|>Davida Kruger is a principal investigator at Henry Ford Health System in Detroit, Michigan, for the study.)\n##\n("entity"<|>BRITTANY DENNIS<|>PERSON<|>Brittany Dennis is a contact for Hoag Memorial Hospital Presbyterian in Newport Beach, California, for the study.)\n##\n("entity"<|>RICHARD BERGENSTAL<|>PERSON<|>Richard Bergenstal is a principal investigator at International Diabetes Center - HealthPartners Institute in Minneapolis, Minnesota, for the study.)\n##\n("entity"<|>SAMANTHA LANGE<|>PERSON<|>Samantha Lange is a contact for Barbara Davis Center in Aurora, Colorado, for the study.)\n##\n("entity"<|>GRAZIA ALEPPO<|>PERSON<|>Grazia Aleppo is a principal investigator at Northwestern University in Evanston, Illinois, for the study.)\n##\n("entity"<|>WYATT LARSON<|>PERSON<|>Wyatt Larson is a contact for Rocky Mountain Clinical Research in Idaho Falls, Idaho, for the study.)\n##\n("entity"<|>JEAN CHEN<|>PERSON<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology in Austin, Texas, for the study.)\n##\n("entity"<|>TINA MITCHELL<|>PERSON<|>Tina Mitchell is a contact for Rainier Clinical Research Center in Renton, Washington, for the study.)\n##\n("entity"<|>RAYHAN LAL<|>PERSON<|>Rayhan Lal is a principal investigator at Stanford University in Stanford, California, for the study.)\n##\n("entity"<|>DORI KHAKPOUR<|>PERSON<|>Dori Khakpour is a contact for University of Washington in Seattle, Washington, for the study.)\n##\n("entity"<|>CAMILLA LEVISTER<|>PERSON<|>Camilla Levister is a principal investigator at Icahn School of Medicine at Mt. Sinai in New York, New York, for the study.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is involved in the study but is not yet recruiting participants.)\n##\n("entity"<|>EXTENDED WEAR INSULIN INFUSION SET<|>EVENT<|>The Extended Wear Insulin Infusion Set (EWIS) is the subject of the investigational study aimed at assessing its use in people with Type 1 Diabetes.)\n##\n("relationship"<|>TANDEM DIABETES CARE, INC.<|>EXTENDED WEAR INSULIN INFUSION SET<|>Tandem Diabetes Care, Inc. is the lead sponsor of the study investigating the Extended Wear Insulin Infusion Set<|>9)\n##\n("relationship"<|>JAEB CENTER FOR HEALTH RESEARCH<|>EXTENDED WEAR INSULIN INFUSION SET<|>Jaeb Center for Health Research collaborates on the study of the Extended Wear Insulin Infusion Set<|>5)\n##\n("relationship"<|>ALAYNE LEHMAN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Alayne Lehman is the study director for the Extended Wear Insulin Infusion Set study<|>8)\n##\n("relationship"<|>JOHN C REED<|>EXTENDED WEAR INSULIN INFUSION SET<|>John C Reed is the principal investigator for the Extended Wear Insulin Infusion Set study at Endocrine Research Solutions<|>8)\n##\n("relationship"<|>DAVIDA KRUGER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Davida Kruger is a principal investigator for the Extended Wear Insulin Infusion Set study at Henry Ford Health System<|>8)\n##\n("relationship"<|>BRITTANY DENNIS<|>EXTENDED WEAR INSULIN INFUSION SET<|>Brittany Dennis is a contact for the Extended Wear Insulin Infusion Set study at Hoag Memorial Hospital Presbyterian<|>5)\n##\n("relationship"<|>RICHARD BERGENSTAL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Richard Bergenstal is a principal investigator for the Extended Wear Insulin Infusion Set study at International Diabetes Center<|>8)\n##\n("relationship"<|>SAMANTHA LANGE<|>EXTENDED WEAR INSULIN INFUSION SET<|>Samantha Lange is a contact for the Extended Wear Insulin Infusion Set study at Barbara Davis Center<|>5)\n##\n("relationship"<|>GRAZIA ALEPPO<|>EXTENDED WEAR INSULIN INFUSION SET<|>Grazia Aleppo is a principal investigator for the Extended Wear Insulin Infusion Set study at Northwestern University<|>8)\n##\n("relationship"<|>WYATT LARSON<|>EXTENDED WEAR INSULIN INFUSION SET<|>Wyatt Larson is a contact for the Extended Wear Insulin Infusion Set study at Rocky Mountain Clinical Research<|>5)\n##\n("relationship"<|>JEAN CHEN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Jean Chen is a principal investigator for the Extended Wear Insulin Infusion Set study at Texas Diabetes and Endocrinology<|>8)\n##\n("relationship"<|>TINA MITCHELL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Tina Mitchell is a contact for the Extended Wear Insulin Infusion Set study at Rainier Clinical Research Center<|>5)\n##\n("relationship"<|>RAYHAN LAL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Rayhan Lal is a principal investigator for the Extended Wear Insulin Infusion Set study at Stanford University<|>8)\n##\n("relationship"<|>DORI KHAKPOUR<|>EXTENDED WEAR INSULIN INFUSION SET<|>Dori Khakpour is a contact for the Extended Wear Insulin Infusion Set study at University of Washington<|>5)\n##\n("relationship"<|>CAMILLA LEVISTER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Camilla Levister is a principal investigator for the Extended Wear Insulin Infusion Set study at Icahn School of Medicine<|>8)\n##\n("relationship"<|>MAYO CLINIC<|>EXTENDED WEAR INSULIN INFUSION SET<|>Mayo Clinic is involved in the Extended Wear Insulin Infusion Set study but is not yet recruiting<|>3)\n<|COMPLETE|>'}]}
2024-12-15 21:56:40,045 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: ("entity"<|>ENDOCRINE RESEARCH SOLUTIONS<|>ORGANIZATION<|>Endocrine Research Solutions is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Roswell, Georgia.)
##
("entity"<|>HENRY FORD HEALTH SYSTEM<|>ORGANIZATION<|>Henry Ford Health System is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Detroit, Michigan.)
##
("entity"<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>ORGANIZATION<|>Hoag Memorial Hospital Presbyterian is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Newport Beach, California.)
##
("entity"<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>ORGANIZATION<|>International Diabetes Center - HealthPartners Institute is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Minneapolis, Minnesota.)
##
("entity"<|>BARBARA DAVIS CENTER<|>ORGANIZATION<|>Barbara Davis Center is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Aurora, Colorado.)
##
("entity"<|>NORTHWESTERN UNIVERSITY<|>ORGANIZATION<|>Northwestern University is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Evanston, Illinois.)
##
("entity"<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>ORGANIZATION<|>Texas Diabetes and Endocrinology is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Austin, Texas.)
##
("entity"<|>RAINIER CLINICAL RESEARCH CENTER<|>ORGANIZATION<|>Rainier Clinical Research Center is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Renton, Washington.)
##
("entity"<|>STANFORD UNIVERSITY<|>ORGANIZATION<|>Stanford University is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Stanford, California.)
##
("entity"<|>UNIVERSITY OF WASHINGTON<|>ORGANIZATION<|>University of Washington is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Seattle, Washington.)
##
("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in New York, New York.)
##
("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a clinical site involved in the study of the Extended Wear Insulin Infusion Set in Rochester, Minnesota.)
##
("relationship"<|>ENDOCRINE RESEARCH SOLUTIONS<|>EXTENDED WEAR INSULIN INFUSION SET<|>Endocrine Research Solutions is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>HENRY FORD HEALTH SYSTEM<|>EXTENDED WEAR INSULIN INFUSION SET<|>Henry Ford Health System is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Hoag Memorial Hospital Presbyterian is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>EXTENDED WEAR INSULIN INFUSION SET<|>International Diabetes Center - HealthPartners Institute is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>BARBARA DAVIS CENTER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Barbara Davis Center is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>NORTHWESTERN UNIVERSITY<|>EXTENDED WEAR INSULIN INFUSION SET<|>Northwestern University is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>EXTENDED WEAR INSULIN INFUSION SET<|>Texas Diabetes and Endocrinology is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>RAINIER CLINICAL RESEARCH CENTER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Rainier Clinical Research Center is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>STANFORD UNIVERSITY<|>EXTENDED WEAR INSULIN INFUSION SET<|>Stanford University is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>UNIVERSITY OF WASHINGTON<|>EXTENDED WEAR INSULIN INFUSION SET<|>University of Washington is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>EXTENDED WEAR INSULIN INFUSION SET<|>Icahn School of Medicine at Mt. Sinai is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
##
("relationship"<|>MAYO CLINIC<|>EXTENDED WEAR INSULIN INFUSION SET<|>Mayo Clinic is a clinical site conducting the Extended Wear Insulin Infusion Set study<|>8)
<|COMPLETE|>
2024-12-15 21:56:40,046 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: # NCTId\nNCT06273124\n# study_url\nhttps://www.clinicaltrials.gov/study/NCT06273124\n# BriefTitle\nInvestigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes\n# OfficialTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n# OverallStatus\nRECRUITING\n# StartDate\n2024-03-07\n# PrimaryCompletionDate\n2025-01-15\n# CompletionDate\n2025-01-15\n# LeadSponsorName\nTandem Diabetes Care, Inc.\n# LeadSponsorClass\nINDUSTRY\n# BriefSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ‚â•250mg/dL for one hour\n# StudyType\nINTERVENTIONAL\n# Phase\n[\'NA\']\n# DesignAllocation\nNA\n# DesignInterventionModel\nSINGLE_GROUP\n# DesignPrimaryPurpose\nTREATMENT\n# DesignMasking\nNONE\n# EnrollmentCount\n260\n# EnrollmentType\nESTIMATED\n# HealthyVolunteers\nFalse\n# Sex\nALL\n# StdAge\n[\'ADULT\', \'OLDER_ADULT\']\n# collaborators\nJaeb Center for Health Research (OTHER)\n# officials\nAlayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)\n# clinical_site_contact\nEndocrine Research Solutions (RECRUITING), Roswell, Georgia, 30076, United States - John C Reed, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Jessica Tapia (CONTACT), 678-878-4750, jtapia.ers@gmail.com | Henry Ford Health System (NOT_YET_RECRUITING), Detroit, Michigan, 48202, United States - Davida Kruger, NP (PRINCIPAL_INVESTIGATOR), NA, NA | Davida Kruger (CONTACT), 313-916-3906, dkruger1@hfhs.org | Hoag Memorial Hospital Presbyterian (RECRUITING), Newport Beach, California, 92663, United States - Brittany Dennis (CONTACT), 949-764-6896, brittany.dennis@hoag.org | David Ahn, MD (PRINCIPAL_INVESTIGATOR), NA, NA | International Diabetes Center - HealthPartners Institute (NOT_YET_RECRUITING), Minneapolis, Minnesota, 55416, United States - Richard Bergenstal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Kathryn Leet, RD,LD, CDCES (CONTACT), 952-993-9793, kathryn.leet@parknicollet.com | Barbara Davis Center (NOT_YET_RECRUITING), Aurora, Colorado, 80045, United States - Samantha Lange (CONTACT), 303-724-7514, samantha.lange@cuanschutz.edu | Erin Cobry, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Northwestern University (NOT_YET_RECRUITING), Evanston, Illinois, 60208, United States - Grazia Aleppo, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Grazia Aleppo (CONTACT), 312-926-5431, aleppo@northwestern.edu | Rocky Mountain Clinical Research (NOT_YET_RECRUITING), Idaho Falls, Idaho, 83404, United States - Wyatt Larson (CONTACT), 208-525-3736, Wyatt.larson@idahomed.com | David Liljenquist, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Texas Diabetes and Endocrinology (NOT_YET_RECRUITING), Austin, Texas, 78731, United States - Jean Chen, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Emmanuel Lopez (CONTACT), 512-334-3505, elopez@texasdiabetes.com | Rainier Clinical Research Center (NOT_YET_RECRUITING), Renton, Washington, 98057, United States - Tina Mitchell (CONTACT), 425-251-1720, TMitchell@rainier-research.com | Frances Broyles, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Stanford University (NOT_YET_RECRUITING), Stanford, California, 94305, United States - Rayhan Lal (CONTACT), 925-727-1317, inforay@stanford.edu | Rayhan Lal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | University of Washington (NOT_YET_RECRUITING), Seattle, Washington, 98109, United States - Dori Khakpour (CONTACT), 206-945-4965, dorik@uw.edu | Irl Hirsch, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota,\n######################\nOutput:', 'role': 'user'}, {'role': 'assistant', 'content': '("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is the lead sponsor of the study investigating an extended wear insulin infusion set for people with Type 1 Diabetes.)\n##\n("entity"<|>JAEB CENTER FOR HEALTH RESEARCH<|>ORGANIZATION<|>Jaeb Center for Health Research is a collaborator in the study.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director at Capillary Biomedical for the insulin infusion set study.)\n##\n("entity"<|>JOHN C REED<|>PERSON<|>John C Reed is the principal investigator at Endocrine Research Solutions in Roswell, Georgia, for the study.)\n##\n("entity"<|>DAVIDA KRUGER<|>PERSON<|>Davida Kruger is a principal investigator at Henry Ford Health System in Detroit, Michigan, for the study.)\n##\n("entity"<|>BRITTANY DENNIS<|>PERSON<|>Brittany Dennis is a contact for Hoag Memorial Hospital Presbyterian in Newport Beach, California, for the study.)\n##\n("entity"<|>RICHARD BERGENSTAL<|>PERSON<|>Richard Bergenstal is a principal investigator at International Diabetes Center - HealthPartners Institute in Minneapolis, Minnesota, for the study.)\n##\n("entity"<|>SAMANTHA LANGE<|>PERSON<|>Samantha Lange is a contact for Barbara Davis Center in Aurora, Colorado, for the study.)\n##\n("entity"<|>GRAZIA ALEPPO<|>PERSON<|>Grazia Aleppo is a principal investigator at Northwestern University in Evanston, Illinois, for the study.)\n##\n("entity"<|>WYATT LARSON<|>PERSON<|>Wyatt Larson is a contact for Rocky Mountain Clinical Research in Idaho Falls, Idaho, for the study.)\n##\n("entity"<|>JEAN CHEN<|>PERSON<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology in Austin, Texas, for the study.)\n##\n("entity"<|>TINA MITCHELL<|>PERSON<|>Tina Mitchell is a contact for Rainier Clinical Research Center in Renton, Washington, for the study.)\n##\n("entity"<|>RAYHAN LAL<|>PERSON<|>Rayhan Lal is a principal investigator at Stanford University in Stanford, California, for the study.)\n##\n("entity"<|>DORI KHAKPOUR<|>PERSON<|>Dori Khakpour is a contact for University of Washington in Seattle, Washington, for the study.)\n##\n("entity"<|>CAMILLA LEVISTER<|>PERSON<|>Camilla Levister is a principal investigator at Icahn School of Medicine at Mt. Sinai in New York, New York, for the study.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is involved in the study but is not yet recruiting participants.)\n##\n("entity"<|>EXTENDED WEAR INSULIN INFUSION SET<|>EVENT<|>The Extended Wear Insulin Infusion Set (EWIS) is the subject of the investigational study aimed at assessing its use in people with Type 1 Diabetes.)\n##\n("relationship"<|>TANDEM DIABETES CARE, INC.<|>EXTENDED WEAR INSULIN INFUSION SET<|>Tandem Diabetes Care, Inc. is the lead sponsor of the study investigating the Extended Wear Insulin Infusion Set<|>9)\n##\n("relationship"<|>JAEB CENTER FOR HEALTH RESEARCH<|>EXTENDED WEAR INSULIN INFUSION SET<|>Jaeb Center for Health Research collaborates on the study of the Extended Wear Insulin Infusion Set<|>5)\n##\n("relationship"<|>ALAYNE LEHMAN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Alayne Lehman is the study director for the Extended Wear Insulin Infusion Set study<|>8)\n##\n("relationship"<|>JOHN C REED<|>EXTENDED WEAR INSULIN INFUSION SET<|>John C Reed is the principal investigator for the Extended Wear Insulin Infusion Set study at Endocrine Research Solutions<|>8)\n##\n("relationship"<|>DAVIDA KRUGER<|>EXTENDED WEAR INSULIN INFUSION SET<|>Davida Kruger is a principal investigator for the Extended Wear Insulin Infusion Set study at Henry Ford Health System<|>8)\n##\n("relationship"<|>BRITTANY DENNIS<|>EXTENDED WEAR INSULIN INFUSION SET<|>Brittany Dennis is a contact for the Extended Wear Insulin Infusion Set study at Hoag Memorial Hospital Presbyterian<|>5)\n##\n("relationship"<|>RICHARD BERGENSTAL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Richard Bergenstal is a principal investigator for the Extended Wear Insulin Infusion Set study at International Diabetes Center<|>8)\n##\n("relationship"<|>SAMANTHA LANGE<|>EXTENDED WEAR INSULIN INFUSION SET<|>Samantha Lange is a contact for the Extended Wear Insulin Infusion Set study at Barbara Davis Center<|>5)\n##\n("relationship"<|>GRAZIA ALEPPO<|>EXTENDED WEAR INSULIN INFUSION SET<|>Grazia Aleppo is a principal investigator for the Extended Wear Insulin Infusion Set study at Northwestern University<|>8)\n##\n("relationship"<|>WYATT LARSON<|>EXTENDED WEAR INSULIN INFUSION SET<|>Wyatt Larson is a contact for the Extended Wear Insulin Infusion Set study at Rocky Mountain Clinical Research<|>5)\n##\n("relationship"<|>JEAN CHEN<|>EXTENDED WEAR INSULIN INFUSION SET<|>Jean Chen is a principal investigator for the Extended Wear Insulin Infusion Set study at Texas Diabetes and Endocrinology<|>8)\n##\n("relationship"<|>TINA MITCHELL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Tina Mitchell is a contact for the Extended Wear Insulin Infusion Set study at Rainier Clinical Research Center<|>5)\n##\n("relationship"<|>RAYHAN LAL<|>EXTENDED WEAR INSULIN INFUSION SET<|>Rayhan Lal is a principal investigator for the E‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îî‚îÄ‚îÄ extract_graph
    ‚îî‚îÄ‚îÄ Verb extract_graph ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚ï∫‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ  33% -:--:-- 0:00:002024-12-15 21:56:40,050 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,050 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'extract-continuation-0', 'history': [{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota, 55905, United States - Yogish Kudva, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Corey Kurek (CONTACT), 507-255-0316, reid.corey@mayo.edu | SUNY Upstate Medical University (RECRUITING), Syracuse, New York, 13210, United States - Suzan Bzdick, RN, CDCES (CONTACT), 315-464-9006, bzdicks@upstate.edu | Ruth Weinstock, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Massachusetts General Hospital (NOT_YET_RECRUITING), Boston, Massachusetts, 2114, United States - Melissa Putman, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Amy Sabean (CONTACT), 617-726-1729, asabean@mgh.harvard.edu\n# conditions\nType1diabetes\n# study_corpus\nNCTId: NCT06273124\n\nStatus: RECRUITING\n\nSponsor: Tandem Diabetes Care, Inc.\n\nPhase: [\'NA\']\n\nTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n\nSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ‚â•250mg/dL for one hour\n\nOfficials: Alayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)Conditions:Type1diabetesEnrollment count: 260\n\nEligibility Criteria\nInclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Age 18 to 80 years old inclusive\n  2. Generally in good health, as determined by the investigator\n  3. Living in the United States with no plans to move outside the United States during the study\n  4. Diagnosis of T1D for at least 12 months\n  5. Minimum of 6 months of insulin pump experience and at least 3 months of current experience with a Tandem pump\n  6. Using Tandem t:slim X2 insulin pump with Control-IQ technology for a minimum of 1 month at the time of enrollment\n  7. Minimum of 14 days of Control-IQ data immediately preceding screening that demonstrate pump use compliance, including at least 85% of time with Control-IQ technology active\n  8. HbA1c \\<9.0% in the last 6 months.\n  9. Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study\n  10. Willing to wear each investigational infusion set for up to 7 days during each of the 12 consecutive wear periods in the study\n  11. Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips\n  12. Access to internet for required periodic uploads of study device data\n  13. BMI in the range 18-35 kg/m2, both inclusive\n  14. Currently using one of the following insulins with no expectation of a need to change insulin type during the study:\n\n      1. Humalog‚Ñ¢\\* (insulin lispro)\n      2. NovoLog‚Ñ¢\\* (insulin aspart)\n  15. Using Humalog‚Ñ¢ insulin lispro or NovoLog‚Ñ¢ insulin aspart for a minimum of 1 month at the time of enrollment\n  16. Willing to change insulin cartridge every 48-72 hours, as recommended by patient\'s healthcare provider during the study\n  17. Has routine access to a smart phone e.g., ability to receive text messages\n  18. Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., English proficient in both verbal and written communication)\n\nExclusion Criteria:\n\n1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)\n2. Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception\n3. Episodes of severe hypoglycemia in the last 6 months resulting in:\n\n   1. Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization)\n   2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1\n######################\nOutput:', 'role': 'user'}, {'role': 'assistant', 'content': '("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a medical school located in New York, involved in various research studies and clinical trials.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a renowned medical center in Rochester, Minnesota, known for its clinical research and patient care.)\n##\n("entity"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>ORGANIZATION<|>SUNY Upstate Medical University is a public medical university in Syracuse, New York, engaged in medical education and research.)\n##\n("entity"<|>MASSACHUSETTS GENERAL HOSPITAL<|>ORGANIZATION<|>Massachusetts General Hospital is a major teaching hospital in Boston, Massachusetts, involved in clinical research and patient care.)\n##\n("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is a company that develops innovative insulin delivery products for people with diabetes.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is a registered nurse and the study director for a clinical trial related to Type 1 diabetes at Capillary Biomedical.)\n##\n("entity"<|>YOGISH KUDVA<|>PERSON<|>Yogish Kudva is a medical doctor and principal investigator at Mayo Clinic, involved in diabetes research.)\n##\n("entity"<|>SUZAN BZDICK<|>PERSON<|>Suzan Bzdick is a registered nurse and contact person for the study at SUNY Upstate Medical University.)\n##\n("entity"<|>RUTH WEINSTOCK<|>PERSON<|>Ruth Weinstock is a medical doctor and principal investigator at SUNY Upstate Medical University, focusing on diabetes research.)\n##\n("entity"<|>COREY KUREK<|>PERSON<|>Corey Kurek is a contact person at Mayo Clinic for the clinical trial.)\n##\n("entity"<|>MELISSA PUTMAN<|>PERSON<|>Melissa Putman is a medical doctor and principal investigator at Massachusetts General Hospital.)\n##\n("entity"<|>AMY SABEAN<|>PERSON<|>Amy Sabean is a contact person at Massachusetts General Hospital for the clinical trial.)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin, requiring ongoing management and research for treatment options.)\n##\n("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is the study director for a clinical trial sponsored by Tandem Diabetes Care, Inc.<|>8)\n##\n("relationship"<|>YOGISH KUDVA<|>MAYO CLINIC<|>Yogish Kudva is a principal investigator at Mayo Clinic, which is involved in diabetes research.<|>7)\n##\n("relationship"<|>SUZAN BZDICK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Suzan Bzdick is a contact person for the study at SUNY Upstate Medical University, which is conducting diabetes research.<|>7)\n##\n("relationship"<|>RUTH WEINSTOCK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on diabetes research.<|>7)\n##\n("relationship"<|>COREY KUREK<|>MAYO CLINIC<|>Corey Kurek is a contact person for the clinical trial at Mayo Clinic.<|>6)\n##\n("relationship"<|>MELISSA PUTMAN<|>MASSACHUSETTS GENERAL HOSPITAL<|>Melissa Putman is a principal investigator at Massachusetts General Hospital, which is involved in diabetes research.<|>7)\n##\n("relationship"<|>AMY SABEAN<|>MASSACHUSETTS GENERAL HOSPITAL<|>Amy Sabean is a contact person for the clinical trial at Massachusetts General Hospital.<|>6)\n##\n("relationship"<|>TYPE 1 DIABETES<|>TANDEM DIABETES CARE, INC.<|>Tandem Diabetes Care, Inc. is sponsoring a clinical trial related to Type 1 diabetes.<|>9)\n##\n("relationship"<|>TYPE 1 DIABETES<|>YOGISH KUDVA<|>Yogish Kudva is involved in research related to Type 1 diabetes at Mayo Clinic.<|>8)\n##\n("relationship"<|>TYPE 1 DIABETES<|>RUTH WEINSTOCK<|>Ruth Weinstock is conducting research on Type 1 diabetes at SUNY Upstate Medical University.<|>8)\n##\n("relationship"<|>TYPE 1 DIABETES<|>MELISSA PUTMAN<|>Melissa Putman is involved in diabetes research at Massachusetts General Hospital.<|>8)\n<|COMPLETE|>'}]}
2024-12-15 21:56:40,051 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: ("entity"<|>NEW YORK<|>GEO<|>New York is a state in the United States where the Icahn School of Medicine at Mt. Sinai is located.)
##
("entity"<|>ROCHESTER<|>GEO<|>Rochester is a city in Minnesota where the Mayo Clinic is located.)
##
("entity"<|>SYRACUSE<|>GEO<|>Syracuse is a city in New York where SUNY Upstate Medical University is located.)
##
("entity"<|>BOSTON<|>GEO<|>Boston is a city in Massachusetts where Massachusetts General Hospital is located.)
##
("entity"<|>MINNESOTA<|>GEO<|>Minnesota is a state in the United States where the Mayo Clinic is located.)
##
("entity"<|>MASSACHUSETTS<|>GEO<|>Massachusetts is a state in the United States where Massachusetts General Hospital is located.)
##
("entity"<|>CONNECTICUT<|>GEO<|>Connecticut is a state in the United States, geographically close to New York and Massachusetts.)
##
("relationship"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>NEW YORK<|>Icahn School of Medicine at Mt. Sinai is located in New York.<|>9)
##
("relationship"<|>MAYO CLINIC<|>ROCHESTER<|>Mayo Clinic is located in Rochester, Minnesota.<|>9)
##
("relationship"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>SYRACUSE<|>SUNY Upstate Medical University is located in Syracuse, New York.<|>9)
##
("relationship"<|>MASSACHUSETTS GENERAL HOSPITAL<|>BOSTON<|>Massachusetts General Hospital is located in Boston, Massachusetts.<|>9)
##
("relationship"<|>MAYO CLINIC<|>MINNESOTA<|>Mayo Clinic is located in the state of Minnesota.<|>9)
##
("relationship"<|>MASSACHUSETTS GENERAL HOSPITAL<|>MASSACHUSETTS<|>Massachusetts General Hospital is located in the state of Massachusetts.<|>9)
##
("relationship"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>NEW YORK<|>SUNY Upstate Medical University is located in New York.<|>9)
<|COMPLETE|>
2024-12-15 21:56:40,051 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota, 55905, United States - Yogish Kudva, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Corey Kurek (CONTACT), 507-255-0316, reid.corey@mayo.edu | SUNY Upstate Medical University (RECRUITING), Syracuse, New York, 13210, United States - Suzan Bzdick, RN, CDCES (CONTACT), 315-464-9006, bzdicks@upstate.edu | Ruth Weinstock, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Massachusetts General Hospital (NOT_YET_RECRUITING), Boston, Massachusetts, 2114, United States - Melissa Putman, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Amy Sabean (CONTACT), 617-726-1729, asabean@mgh.harvard.edu\n# conditions\nType1diabetes\n# study_corpus\nNCTId: NCT06273124\n\nStatus: RECRUITING\n\nSponsor: Tandem Diabetes Care, Inc.\n\nPhase: [\'NA\']\n\nTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n\nSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ‚â•250mg/dL for one hour\n\nOfficials: Alayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)Conditions:Type1diabetesEnrollment count: 260\n\nEligibility Criteria\nInclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Age 18 to 80 years old inclusive\n  2. Generally in good health, as determined by the investigator\n  3. Living in the United States with no plans to move outside the United States during the study\n  4. Diagnosis of T1D for at least 12 months\n  5. Minimum of 6 months of insulin pump experience and at least 3 months of current experience with a Tandem pump\n  6. Using Tandem t:slim X2 insulin pump with Control-IQ technology for a minimum of 1 month at the time of enrollment\n  7. Minimum of 14 days of Control-IQ data immediately preceding screening that demonstrate pump use compliance, including at least 85% of time with Control-IQ technology active\n  8. HbA1c \\<9.0% in the last 6 months.\n  9. Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study\n  10. Willing to wear each investigational infusion set for up to 7 days during each of the 12 consecutive wear periods in the study\n  11. Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips\n  12. Access to internet for required periodic uploads of study device data\n  13. BMI in the range 18-35 kg/m2, both inclusive\n  14. Currently using one of the following insulins with no expectation of a need to change insulin type during the study:\n\n      1. Humalog‚Ñ¢\\* (insulin lispro)\n      2. NovoLog‚Ñ¢\\* (insulin aspart)\n  15. Using Humalog‚Ñ¢ insulin lispro or NovoLog‚Ñ¢ insulin aspart for a minimum of 1 month at the time of enrollment\n  16. Willing to change insulin cartridge every 48-72 hours, as recommended by patient\'s healthcare provider during the study\n  17. Has routine access to a smart phone e.g., ability to receive text messages\n  18. Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., English proficient in both verbal and written communication)\n\nExclusion Criteria:\n\n1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)\n2. Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception\n3. Episodes of severe hypoglycemia in the last 6 months resulting in:\n\n   1. Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization)\n   2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1\n######################\nOutput:', 'role': 'user'}, {'role': 'assistant', 'content': '("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a medical school located in New York, involved in various research studies and clinical trials.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a renowned medical center in Rochester, Minnesota, known for its clinical research and patient care.)\n##\n("entity"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>ORGANIZATION<|>SUNY Upstate Medical University is a public medical university in Syracuse, New York, engaged in medical education and research.)\n##\n("entity"<|>MASSACHUSETTS GENERAL HOSPITAL<|>ORGANIZATION<|>Massachusetts General Hospital is a major teaching hospital in Boston, Massachusetts, involved in clinical research and patient care.)\n##\n("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is a company that develops innovative insulin delivery products for people with diabetes.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is a registered nurse and the study director for a clinical trial related to Type 1 diabetes at Capillary Biomedical.)\n##\n("entity"<|>YOGISH KUDVA<|>PERSON<|>Yogish Kudva is a medical doctor and principal investigator at Mayo Clinic, involved in diabetes research.)\n##\n("entity"<|>SUZAN BZDICK<|>PERSON<|>Suzan Bzdick is a registered nurse and contact person for the study at SUNY Upstate Medical University.)\n##\n("entity"<|>RUTH WEINSTOCK<|>PERSON<|>Ruth Weinstock is a medical doctor and principal investigator at SUNY Upstate Medical University, focusing on diabetes research.)\n##\n("entity"<|>COREY KUREK<|>PERSON<|>Corey Kurek is a contact person at Mayo Clinic for the clinical trial.)\n##\n("entity"<|>MELISSA PUTMAN<|>PERSON<|>Melissa Putman is a medical doctor and principal investigator at Massachusetts General Hospital.)\n##\n("entity"<|>AMY SABEAN<|>PERSON<|>Amy Sabean is a contact person at Massachusetts General Hospital for the clinical trial.)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin, requiring ongoing management and research for treatment options.)\n##\n("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is the study director for a clinical trial sponsored by Tandem Diabetes Care, Inc.<|>8)\n##\n("relationship"<|>YOGISH KUDVA<|>MAYO CLINIC<|>Yogish Kudva is a principal investigator at Mayo Clinic, which is involved in diabetes research.<|>7)\n##\n("relationship"<|>SUZAN BZDICK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Suzan Bzdick is a contact person for the study at SUNY Upstate Medical University, which is conducting diabetes research.<|>7)\n##\n("relationship"<|>RUTH WEINSTOCK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on diabetes research.<|>7)\n##\n("relationship"<|>COREY KUREK<|>MAYO CLINIC<|>Corey Kurek is a contact person for the clinical trial at Mayo Clinic.<|>6)\n##\n("relationship"<|>MELISSA PUTMAN<|>MASSACHUSETTS GENERAL HOSPITAL<|>Melissa Putman is a principal investigator at Massachusetts General Hospital, which is involved in diabetes research.<|>7)\n##\n("relationship"<|>AMY SABEAN<|>MASSACHUSETTS GENERAL HOSPITAL<|>Amy Sabean is a contact person for the clinical trial at Massachusetts General Hospital.<|>6)\n##\n("relationship"<|>TYPE 1 DIABETES<|>TANDEM DIABETES CARE, INC.<|>Tandem Diabetes Care, Inc. is sponsoring a clinical trial related to Type 1 diabetes.<|>9)\n##\n("relationship"<|>TYPE 1 DIABETES<|>YOGISH KUDVA<|>Yogish Kudva is involved in research related to Type 1 diabetes at Mayo Clinic.<|>8)\n##\n("relationship"<|>TYPE 1 DIABETES<|>RUTH WEINSTOCK<|>Ruth Weinstock is conducting research on Type 1 diabetes at SUNY Upstate Medical University.<|>8)\n##\n("relationship"<|>TYPE 1 DIABETES<|>MELISSA PUTMAN<|>Melissa Putman is involved in diabetes research at Massachusetts General Hospital.<|>8)\n<|COMPLETE|>'}]
2024-12-15 21:56:40,051 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:40,051 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 4000, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:40,052 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,052 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'extract-continuation-0', 'history': [{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1. Cushing\'s Disease\n   2. Pancreatic islet cell tumor\n   3. Insulinoma\n   4. Lipodystrophy\n   5. Extensive lipohypertrophy, as assessed by the investigator\n8. Currently undergoing treatment with:\n\n   1. Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening),\n   2. Thyroid hormones, unless use has been stable during the past 3 months\n9. Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation:\n\n   1. Alcoholism\n   2. Drug abuse\n10. Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results\n11. Current participation in another clinical drug or device study\n12. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Capillary BiomedicalStart Date:2024-03-07Completion Date:2025-01-15\n\nDetailed Description\nThis is a multi-center, single-arm, prospective study of an extended wear infusion set in adults with Type 1 diabetes using a Tandem t:slim X2 insulin pump with Control-IQ technology with continuous Glucose Monitoring (CGM). Up to 300 participants across the United States age 18-80 will be enrolled in up to 20 investigational centers. Participants will change insulin cartridge every 48 to 72 hours as recommended by their health care provider. Participants will be expected to participate in the study for approximately 12-16 weeks.\n######################\nOutput:', 'role': 'user'}, {'role': 'assistant', 'content': '("entity"<|>CAPILLARY BIOMEDICAL<|>ORGANIZATION<|>Capillary Biomedical is the organization conducting the clinical study involving an extended wear infusion set for adults with Type 1 diabetes.)\n##\n("entity"<|>TANDEM T:SLIM X2<|>ORGANIZATION<|>Tandem t:slim X2 is an insulin pump used in the study with Control-IQ technology and continuous Glucose Monitoring (CGM).)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 diabetes is the condition being studied in the clinical trial involving the extended wear infusion set.)\n##\n("entity"<|>UNITED STATES<|>GEO<|>The United States is the country where the clinical study will take place, enrolling participants from various locations.)\n##\n("entity"<|>START DATE<|>EVENT<|>The study is set to begin on March 7, 2024, marking the start of participant enrollment and data collection.)\n##\n("entity"<|>COMPLETION DATE<|>EVENT<|>The study is expected to be completed by January 15, 2025, concluding the data collection and analysis phase.)\n##\n("entity"<|>PARTICIPANTS<|>PERSON<|>Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers.)\n##\n("relationship"<|>CAPILLARY BIOMEDICAL<|>TANDEM T:SLIM X2<|>Capillary Biomedical is conducting a study that utilizes the Tandem t:slim X2 insulin pump for Type 1 diabetes management<|>8)\n##\n("relationship"<|>TYPE 1 DIABETES<|>CAPILLARY BIOMEDICAL<|>The study by Capillary Biomedical focuses on Type 1 diabetes and its management through an extended wear infusion set<|>9)\n##\n("relationship"<|>UNITED STATES<|>CAPILLARY BIOMEDICAL<|>The clinical study conducted by Capillary Biomedical will take place in the United States<|>7)\n##\n("relationship"<|>START DATE<|>CAPILLARY BIOMEDICAL<|>The study conducted by Capillary Biomedical is set to start on March 7, 2024<|>6)\n##\n("relationship"<|>COMPLETION DATE<|>CAPILLARY BIOMEDICAL<|>The study conducted by Capillary Biomedical is expected to be completed by January 15, 2025<|>6)\n##\n("relationship"<|>PARTICIPANTS<|>CAPILLARY BIOMEDICAL<|>Up to 300 participants will be enrolled in the study conducted by Capillary Biomedical<|>8)\n<|COMPLETE|>'}]}
2024-12-15 21:56:40,053 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: ("entity"<|>CUSHING'S DISEASE<|>EVENT<|>Cushing's Disease is a condition listed as a known history that may affect study participation and safety in the clinical trial.)
##
("entity"<|>PANCREATIC ISLET CELL TUMOR<|>EVENT<|>Pancreatic islet cell tumor is a condition that may compromise safety or successful participation in the clinical study.)
##
("entity"<|>INSULINOMA<|>EVENT<|>Insulinoma is a condition that is considered relevant to the safety and integrity of study results.)
##
("entity"<|>LIPODYSTROPHY<|>EVENT<|>Lipodystrophy is a known condition that may affect the safety or successful participation in the clinical trial.)
##
("entity"<|>EXTENSIVE LIPOHYPERTROPHY<|>EVENT<|>Extensive lipohypertrophy is a condition assessed by the investigator that may impact study participation.)
##
("entity"<|>ALCOHOLISM<|>EVENT<|>Alcoholism is a significant history that may compromise safety or successful study participation.)
##
("entity"<|>DRUG ABUSE<|>EVENT<|>Drug abuse is a significant history that may interfere with the safety or integrity of study results.)
##
("entity"<|>SIGNIFICANT ACUTE OR CHRONIC ILLNESS<|>EVENT<|>Significant acute or chronic illness is a condition that may affect the safety or integrity of study results.)
##
("entity"<|>CURRENT PARTICIPATION IN ANOTHER CLINICAL DRUG OR DEVICE STUDY<|>EVENT<|>Current participation in another clinical drug or device study may affect eligibility for the study conducted by Capillary Biomedical.)
<|COMPLETE|>
2024-12-15 21:56:40,053 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1. Cushing\'s Disease\n   2. Pancreatic islet cell tumor\n   3. Insulinoma\n   4. Lipodystrophy\n   5. Extensive lipohypertrophy, as assessed by the investigator\n8. Currently undergoing treatment with:\n\n   1. Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening),\n   2. Thyroid hormones, unless use has been stable during the past 3 months\n9. Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation:\n\n   1. Alcoholism\n   2. Drug abuse\n10. Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results\n11. Current participation in another clinical drug or device study\n12. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Capillary BiomedicalStart Date:2024-03-07Completion Date:2025-01-15\n\nDetailed Description\nThis is a multi-center, single-arm, prospective study of an extended wear infusion set in adults with Type 1 diabetes using a Tandem t:slim X2 insulin pump with Control-IQ technology with continuous Glucose Monitoring (CGM). Up to 300 participants across the United States age 18-80 will be enrolled in up to 20 investigational centers. Participants will change insulin cartridge every 48 to 72 hours as recommended by their health care provider. Participants will be expected to participate in the study for approximately 12-16 weeks.\n######################\nOutput:', 'role': 'user'}, {'role': 'assistant', 'content': '("entity"<|>CAPILLARY BIOMEDICAL<|>ORGANIZATION<|>Capillary Biomedical is the organization conducting the clinical study involving an extended wear infusion set for adults with Type 1 diabetes.)\n##\n("entity"<|>TANDEM T:SLIM X2<|>ORGANIZATION<|>Tandem t:slim X2 is an insulin pump used in the study with Control-IQ technology and continuous Glucose Monitoring (CGM).)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 diabetes is the condition being studied in the clinical trial involving the extended wear infusion set.)\n##\n("entity"<|>UNITED STATES<|>GEO<|>The United States is the country where the clinical study will take place, enrolling participants from various locations.)\n##\n("entity"<|>START DATE<|>EVENT<|>The study is set to begin on March 7, 2024, marking the start of participant enrollment and data collection.)\n##\n("entity"<|>COMPLETION DATE<|>EVENT<|>The study is expected to be completed by January 15, 2025, concluding the data collection and analysis phase.)\n##\n("entity"<|>PARTICIPANTS<|>PERSON<|>Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers.)\n##\n("relationship"<|>CAPILLARY BIOMEDICAL<|>TANDEM T:SLIM X2<|>Capillary Biomedical is conducting a study that utilizes the Tandem t:slim X2 insulin pump for Type 1 diabetes management<|>8)\n##\n("relationship"<|>TYPE 1 DIABETES<|>CAPILLARY BIOMEDICAL<|>The study by Capillary Biomedical focuses on Type 1 diabetes and its management through an extended wear infusion set<|>9)\n##\n("relationship"<|>UNITED STATES<|>CAPILLARY BIOMEDICAL<|>The clinical study conducted by Capillary B *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
‚†á GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îî‚îÄ‚îÄ extract_graph2024-12-15 21:56:40,516 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,516 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:56:40,516 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: Type 1 diabetes is a chronic condition characterized by the pancreas's inability to produce sufficient insulin, necessitating continuous management and research to explore effective treatment options. This condition is currently the focus of a clinical trial that is investigating the use of an extended wear infusion set, which aims to improve the management of insulin delivery for individuals living with Type 1 diabetes.
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:40,517 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 500, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:56:40,517 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: Mayo Clinic is a renowned medical center located in Rochester, Minnesota, recognized for its excellence in clinical research and patient care. Currently, it is involved in the study of the Extended Wear Insulin Infusion Set, although it is not yet recruiting participants for this study.
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:40,517 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 500, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:56:40,517 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: Alayne Lehman is a registered nurse and serves as the study director for clinical trials at Capillary Biomedical. She is specifically involved in a clinical trial related to Type 1 diabetes, overseeing the study focused on the insulin infusion set.
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:40,517 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:40,517 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 500, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:40,518 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,518 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:56:40,518 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: Tandem Diabetes Care, Inc. is a company dedicated to developing innovative insulin delivery products specifically designed for individuals with diabetes. The company is also the lead sponsor of a study that investigates an extended wear insulin infusion set aimed at improving the management of diabetes for people with Type 1 Diabetes.
2024-12-15 21:56:40,518 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:40,518 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:40,518 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 500, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:40,518 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:40,518 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:56:40,518 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: The Icahn School of Medicine at Mt. Sinai is a prominent medical school located in New York, New York. It is actively engaged in various research studies and clinical trials, including its role as a clinical site for the study of the Extended Wear Insulin Infusion Set. The institution is recognized for its contributions to medical research and education, making it a significant player in üöÄ extract_graph
Empty DataFrame
Columns: []
Index: []
‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†º GraphRAG Indexer 
üöÄ compute_communities
Empty DataFrame
Columns: []
Index: []
‚†ã GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†ô GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ create_final_entities
                                      id  human_readable_id                                              title          type                                        description                                      text_unit_ids
0   908e379b-e8d1-4dc7-be32-c967a71807a4                  0                         TANDEM DIABETES CARE, INC.  ORGANIZATION  Tandem Diabetes Care, Inc. is a company dedica...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
1   a3490882-513f-4c85-b1b0-65bcf79d6aa3                  1                    JAEB CENTER FOR HEALTH RESEARCH  ORGANIZATION  Jaeb Center for Health Research is a collabora...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
2   aaa7ca6d-608f-4ee7-9bbf-a406980ccc29                  2                                      ALAYNE LEHMAN        PERSON  Alayne Lehman is a registered nurse and serves...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
3   b6c1ffe7-36d4-4acd-be13-2c18529effe0                  3                                        JOHN C REED        PERSON  John C Reed is the principal investigator at E...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
4   6a0357bd-1753-4eb9-9616-d98477592dbc                  4                                      DAVIDA KRUGER        PERSON  Davida Kruger is a principal investigator at H...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
5   b1cd393b-64cc-407e-bddf-6afeac5c3ba4                  5                                    BRITTANY DENNIS        PERSON  Brittany Dennis is a contact for Hoag Memorial...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
6   03b2b5e0-e0fb-4d2c-8182-8c9d9c2eaa2a                  6                                 RICHARD BERGENSTAL        PERSON  Richard Bergenstal is a principal investigator...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
7   f1cb7990-08e3-45fe-977c-7e28c5528280                  7                                     SAMANTHA LANGE        PERSON  Samantha Lange is a contact for Barbara Davis ...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
8   7f6ba670-2db8-448e-b1c5-0edf2f578907                  8                                      GRAZIA ALEPPO        PERSON  Grazia Aleppo is a principal investigator at N...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
9   8ddfb07e-7b56-45db-8f49-971fc7d5d2b4                  9                                       WYATT LARSON        PERSON  Wyatt Larson is a contact for Rocky Mountain C...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
10  09dd480a-3dd8-499b-9390-9f287bf5e66f                 10                                          JEAN CHEN        PERSON  Jean Chen is a principal investigator at Texas...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
11  18139ae3-a441-48e1-b6c9-fc1be7282717                 11                                      TINA MITCHELL        PERSON  Tina Mitchell is a contact for Rainier Clinica...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
12  0c766ec0-0059-4e3c-b1b4-42b637061769                 12                                         RAYHAN LAL        PERSON  Rayhan Lal is a principal investigator at Stan...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
13  157d2eaa-7726-4f18-8435-cf93e1686f7b                 13                                      DORI KHAKPOUR        PERSON  Dori Khakpour is a contact for University of W...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
14  32079101-61a5-4cbd-9161-e8ed225c52e9                 14                                   CAMILLA LEVISTER        PERSON  Camilla Levister is a principal investigator a...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
15  7e874f82-f87c-48e4-a1ab-2e20497e8a81                 15                                        MAYO CLINIC  ORGANIZATION  Mayo Clinic is a renowned medical center locat...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
16  68d0c128-4506-4e70-b6bb-260ef7460b75                 16                 EXTENDED WEAR INSULIN INFUSION SET         EVENT  The Extended Wear Insulin Infusion Set (EWIS) ...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
17  bbbe945a-db9e-4cb6-8325-c4cfa11b27be                 17                           HENRY FORD HEALTH SYSTEM  ORGANIZATION  Henry Ford Health System is a clinical site in...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
18  b9f31ada-5ca3-4b46-8870-d8fd94edf05c                 18                HOAG MEMORIAL HOSPITAL PRESBYTERIAN  ORGANIZATION  Hoag Memorial Hospital Presbyterian is a clini...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
19  6bb5b0d1-c24c-4119-bce1-5be518c99817                 19  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...  ORGANIZATION  International Diabetes Center - HealthPartners...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
20  1e6edc99-41d4-49d6-a619-49c3a31305aa                 20                               BARBARA DAVIS CENTER  ORGANIZATION  Barbara Davis Center is a clinical site involv...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
21  a60f7332-09fa-4228-8b59-4ba3c543d993                 21                            NORTHWESTERN UNIVERSITY  ORGANIZATION  Northwestern University is a clinical site inv...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
22  dd4917b0-af46-4be7-af68-dc31216f003e                 22                   TEXAS DIABETES AND ENDOCRINOLOGY  ORGANIZATION  Texas Diabetes and Endocrinology is a clinical...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
23  2c511ac6-2410-422c-972c-3fc9afbdbf05                 23                   RAINIER CLINICAL RESEARCH CENTER  ORGANIZATION  Rainier Clinical Research Center is a clinical...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
24  5110c732-134e-4145-a804-9eb4da7d4d29                 24                                STANFORD UNIVERSITY  ORGANIZATION  Stanford University is a clinical site involve...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
25  1ca72b77-8251-4cca-8788-a4d62471fc3d                 25                           UNIVERSITY OF WASHINGTON  ORGANIZATION  University of Washington is a clinical site in...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
26  4c14cfcd-816d-4b02-9751-3296cc5989be                 26              ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ORGANIZATION  The Icahn School of Medicine at Mt. Sinai is a...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
27  9b2de6c0-256c-4bed-a45f-032cdfa47a3a                 27                       ENDOCRINE RESEARCH SOLUTIONS                                                                   [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
28  0d8bde39-c8ab-48a4-8da6-a165ca2ea71d                 28                    SUNY UPSTATE MEDICAL UNIVERSITY  ORGANIZATION  SUNY Upstate Medical University is a public me...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
29  e5a2b981-d8d3-4e2b-bd80-0eb662af2342                 29                     MASSACHUSETTS GENERAL HOSPITAL  ORGANIZATION  Massachusetts General Hospital is a major teac...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
30  e1f6655b-7020-4253-9d8c-a716b7654405                 30                                       YOGISH KUDVA        PERSON  Yogish Kudva is a medical doctor and principal...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
31  fa503b27-431d-4eea-b3c5-b52e329d02af                 31                                       SUZAN BZDICK        PERSON  Suzan Bzdick is a registered nurse and contact...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
32  f9a5fef1-9afc-4a5c-a4ad-91440147829e                 32                                     RUTH WEINSTOCK        PERSON  Ruth Weinstock is a medical doctor and princip...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
33  5ab5095d-90ea-4786-bae8-21acc3083a83                 33                                        COREY KUREK        PERSON  Corey Kurek is a contact person at Mayo Clinic...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
34  1fabd86f-660d-4ea2-bb29-ce215e356e32                 34                                     MELISSA PUTMAN        PERSON  Melissa Putman is a medical doctor and princip...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
35  a3203481-5a5f-4f53-b4e2-5746406e3645                 35                                         AMY SABEAN        PERSON  Amy Sabean is a contact person at Massachusett...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
36  fad021a2-24b4-4be2-b576-4f85fd90e446                 36                                    TYPE 1 DIABETES         EVENT  Type 1 diabetes is a chronic condition charact...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
37  4b292758-76b9-4fae-9193-6461e14504f5                 37                                          ROCHESTER           GEO  Rochester is a city in Minnesota where the May...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
38  85c34762-f717-4a2b-a7e7-c0b54df3aea2                 38                                           SYRACUSE           GEO  Syracuse is a city in New York where SUNY Upst...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
39  4083c7c9-7d70-406a-ad47-edd38692f90d                 39                                             BOSTON           GEO  Boston is a city in Massachusetts where Massac...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
40  8be220b3-6ae8-4b43-a99f-c891ad7f1a61                 40                                          MINNESOTA           GEO  Minnesota is a state in the United States wher...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
41  4f2f1709-3ffb-4d86-ac4f-f6bd759f72fb                 41                                      MASSACHUSETTS           GEO  Massachusetts is a state in the United States ...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
42  ce1f2e83-a01c-4d43-88ae-60a416ffc18b                 42                                           NEW YORK                                                                   [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
43  eef030c7-a036-4e6f-9e09-6c30555b98a6                 43                               CAPILLARY BIOMEDICAL  ORGANIZATION  Capillary Biomedical is the organization condu...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
44  d7b0344b-0195-4f0f-b348-2110fef1c2e2                 44                                   TANDEM T:SLIM X2  ORGANIZATION  Tandem t:slim X2 is an insulin pump used in th...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
45  6ea7240e-4499-4fbb-ab0e-b85511766570                 45                                      UNITED STATES           GEO  The United States is the country where the cli...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
46  15cc1d82-88da-469d-8ea5-6d8311863ccc                 46                                         START DATE         EVENT  The study is set to begin on March 7, 2024, ma...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
47  6287d663-8f61-4b38-84cc-11d8c33399a6                 47                                    COMPLETION DATE         EVENT  The study is expected to be completed by Janua...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
48  366afc6c-39d3-4d39-9f1a-a9147f79c530                 48                                       PARTICIPANTS        PERSON  Up to 300 participants aged 18-80 will be enro...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
‚†ô GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†π GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ create_final_relationships
                                      id  human_readable_id                                 source  ... weight combined_degree                                      text_unit_ids
0   31dffae0-69f2-48cb-86be-18604dd5fbca                  0             TANDEM DIABETES CARE, INC.  ...    9.0              30  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
1   c08d0280-8b4f-42e3-b161-d5992f192531                  1        JAEB CENTER FOR HEALTH RESEARCH  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
2   596ae0c7-5857-4405-9ac3-a7559703c48f                  2                          ALAYNE LEHMAN  ...    8.0              29  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
3   6e153b3f-ea2c-487d-b61d-a5c74ff5d952                  3                            JOHN C REED  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
4   169b0cd0-27d9-4737-8719-5578c9f32a38                  4                          DAVIDA KRUGER  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
5   9b727388-e945-46ba-bde0-28ff8f52f9cb                  5                        BRITTANY DENNIS  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
6   477987e2-1caa-4764-9e8b-c9e02ddfd5c8                  6                     RICHARD BERGENSTAL  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
7   5f442542-9ca5-432f-9abc-047bdc843b56                  7                         SAMANTHA LANGE  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
8   c6609ca5-491f-4de2-8a6e-9e00b3455730                  8                          GRAZIA ALEPPO  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
9   3ed35160-5489-44b9-902b-9a7bb87ba46c                  9                           WYATT LARSON  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
10  cfe94da2-52a9-43c2-bbb2-18be01ec99c4                 10                              JEAN CHEN  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
11  412e9ce0-e3e8-4523-aa1f-967fa43b68ae                 11                          TINA MITCHELL  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
12  07047764-9f43-4aeb-9985-d1193c6d6df1                 12                             RAYHAN LAL  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
13  48d2dc08-7e1f-492e-983d-99df96868a68                 13                          DORI KHAKPOUR  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
14  e1ecb61b-a04d-4e7e-a966-7fcc2b3ac54b                 14                       CAMILLA LEVISTER  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
15  1242d871-bf01-48f3-9cd9-fda8b677323b                 15                            MAYO CLINIC  ...    2.0              32  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
16  fad87ede-7796-4a0b-9494-11013c662367                 16     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
17  6cc09674-6585-435b-9eba-92066510e07f                 17     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
18  7ea0653e-6a61-4527-a718-8ea4d7f7d48e                 18     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
19  60a49f1d-a753-481c-a2ea-232effefc3d0                 19     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
20  007704bc-ccc3-41dc-a76d-8daf90b3c2be                 20     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
21  fa5e0c1a-9d05-4fd1-b5dd-2b348d0e7f78                 21     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
22  66aad45d-50c6-46e3-872a-1da66ad7e250                 22     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
23  ff57dacc-4503-4103-b77a-724e038f33df                 23     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
24  8ff834ff-14a9-4758-a378-009ad881a004                 24     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
25  ee7cbcbb-fefa-4e12-ad49-221fa7b81470                 25     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
26  3f537a3c-00a8-44fc-b35b-1f436aadb309                 26     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              29  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
27  ee326d38-77e0-452f-ae47-245ae3093c73                 27  ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ...    9.0               4  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
28  bf6db7a5-760b-4095-88fb-834cc7bdbe93                 28                            MAYO CLINIC  ...    7.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
29  138048ef-7e7e-475d-a87c-2fe75319287a                 29                            MAYO CLINIC  ...    6.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
30  c1951f1d-5c31-42e3-94cb-4dcec1a774a5                 30                            MAYO CLINIC  ...    9.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
31  878f5515-6f14-4ecf-89c3-b44694427476                 31                            MAYO CLINIC  ...    9.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
32  80721192-8eed-48a3-bde9-e9d871cf4151                 32        SUNY UPSTATE MEDICAL UNIVERSITY  ...    7.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
33  7fd1ea33-61e9-4e94-bc94-dbc504e987a6                 33        SUNY UPSTATE MEDICAL UNIVERSITY  ...    7.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
34  2178b77b-8155-4c84-80f3-cf5a54ad2995                 34        SUNY UPSTATE MEDICAL UNIVERSITY  ...    9.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
35  47b03bf6-332b-44ae-b881-f21a95f5232b                 35        SUNY UPSTATE MEDICAL UNIVERSITY  ...    1.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
36  7f21e245-6cf1-4035-876b-ab544b864f4a                 36         MASSACHUSETTS GENERAL HOSPITAL  ...    7.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
37  956fc4cb-da5a-4a51-a314-8077784cafd9                 37         MASSACHUSETTS GENERAL HOSPITAL  ...    6.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
38  b919edb3-de55-4d68-b91f-55fcd17d7963                 38         MASSACHUSETTS GENERAL HOSPITAL  ...    9.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
39  d287a59e-4581-418d-974e-d9744c3cbf79                 39         MASSACHUSETTS GENERAL HOSPITAL  ...    9.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
40  b8029f72-58c4-4338-85e4-bf5619df65cc                 40             TANDEM DIABETES CARE, INC.  ...    8.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
41  69723cad-462f-40c1-a511-c8b3354d4341                 41             TANDEM DIABETES CARE, INC.  ...    9.0               8  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
42  c85f9494-dfb4-4286-a7c3-781a96d712b9                 42                           YOGISH KUDVA  ...    8.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
43  18a06d30-73a1-4729-a3e9-a6be7542a943                 43                         RUTH WEINSTOCK  ...    8.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
44  591f752c-3879-429d-9f1b-08fd36c41ad0                 44                         MELISSA PUTMAN  ...    1.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
45  0c39c660-33fc-4dc0-8001-d64028e94088                 45                   CAPILLARY BIOMEDICAL  ...    8.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
46  29c435e1-6b07-4375-9fef-0dd4b8c2c031                 46                   CAPILLARY BIOMEDICAL  ...    9.0              11  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
47  496fee36-5ffc-4ff5-a797-d594385e3fa6                 47                   CAPILLARY BIOMEDICAL  ...    7.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
48  16177ee6-06bf-4c7d-9fdc-5aa333c3575c                 48                   CAPILLARY BIOMEDICAL  ...    6.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
49  5e40f8db-905e-4cc3-8c54-de0d9e725d18                 49                   CAPILLARY BIOMEDICAL  ...    6.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
50  15054e25-e9ca-43f8-bfbd-6309087347b8                 50                   CAPILLARY BIOMEDICAL  ...    1.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...

[51 rows x 8 columns]
‚†∏ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†º GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ create_final_communities
                                     id human_readable_id community  parent  ...                                   relationship_ids                                      text_unit_ids      period size
0  56e3110f-6d1d-490c-86eb-45a2a17fb006                 0         0      -1  ...  [138048ef-7e7e-475d-a87c-2fe75319287a, 69723ca...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    8
1  c167c039-7dc5-4ab3-bc95-c19d35f196ab                 1         1      -1  ...  [007704bc-ccc3-41dc-a76d-8daf90b3c2be, 0704776...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...  2024-12-15   24
2  404328f7-ecc8-477e-b05b-1679ef45c80d                 2         2      -1  ...  [7f21e245-6cf1-4035-876b-ab544b864f4a, 956fc4c...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    5
3  450bae1f-b4b6-4e7f-a538-be52127de1b6                 3         3      -1  ...  [0c39c660-33fc-4dc0-8001-d64028e94088, 15054e2...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...  2024-12-15    6
4  b4c3a6db-4ffb-41c4-9e6c-ca8725d41fc7                 4         4      -1  ...  [2178b77b-8155-4c84-80f3-cf5a54ad2995, 47b03bf...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    6

[5 rows x 11 columns]
‚†º GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚†¥ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ create_final_nodes
                                      id  human_readable_id                                              title  community  level  degree  x  y
0   908e379b-e8d1-4dc7-be32-c967a71807a4                  0                         TANDEM DIABETES CARE, INC.          0      0       3  0  0
1   a3490882-513f-4c85-b1b0-65bcf79d6aa3                  1                    JAEB CENTER FOR HEALTH RESEARCH          1      0       1  0  0
2   aaa7ca6d-608f-4ee7-9bbf-a406980ccc29                  2                                      ALAYNE LEHMAN          0      0       2  0  0
3   b6c1ffe7-36d4-4acd-be13-2c18529effe0                  3                                        JOHN C REED          1      0       1  0  0
4   6a0357bd-1753-4eb9-9616-d98477592dbc                  4                                      DAVIDA KRUGER          1      0       1  0  0
5   b1cd393b-64cc-407e-bddf-6afeac5c3ba4                  5                                    BRITTANY DENNIS          1      0       1  0  0
6   03b2b5e0-e0fb-4d2c-8182-8c9d9c2eaa2a                  6                                 RICHARD BERGENSTAL          1      0       1  0  0
7   f1cb7990-08e3-45fe-977c-7e28c5528280                  7                                     SAMANTHA LANGE          1      0       1  0  0
8   7f6ba670-2db8-448e-b1c5-0edf2f578907                  8                                      GRAZIA ALEPPO          1      0       1  0  0
9   8ddfb07e-7b56-45db-8f49-971fc7d5d2b4                  9                                       WYATT LARSON          1      0       1  0  0
10  09dd480a-3dd8-499b-9390-9f287bf5e66f                 10                                          JEAN CHEN          1      0       1  0  0
11  18139ae3-a441-48e1-b6c9-fc1be7282717                 11                                      TINA MITCHELL          1      0       1  0  0
12  0c766ec0-0059-4e3c-b1b4-42b637061769                 12                                         RAYHAN LAL          1      0       1  0  0
13  157d2eaa-7726-4f18-8435-cf93e1686f7b                 13                                      DORI KHAKPOUR          1      0       1  0  0
14  32079101-61a5-4cbd-9161-e8ed225c52e9                 14                                   CAMILLA LEVISTER          1      0       1  0  0
15  7e874f82-f87c-48e4-a1ab-2e20497e8a81                 15                                        MAYO CLINIC          0      0       5  0  0
16  68d0c128-4506-4e70-b6bb-260ef7460b75                 16                 EXTENDED WEAR INSULIN INFUSION SET          1      0      27  0  0
17  bbbe945a-db9e-4cb6-8325-c4cfa11b27be                 17                           HENRY FORD HEALTH SYSTEM          1      0       1  0  0
18  b9f31ada-5ca3-4b46-8870-d8fd94edf05c                 18                HOAG MEMORIAL HOSPITAL PRESBYTERIAN          1      0       1  0  0
19  6bb5b0d1-c24c-4119-bce1-5be518c99817                 19  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...          1      0       1  0  0
20  1e6edc99-41d4-49d6-a619-49c3a31305aa                 20                               BARBARA DAVIS CENTER          1      0       1  0  0
21  a60f7332-09fa-4228-8b59-4ba3c543d993                 21                            NORTHWESTERN UNIVERSITY          1      0       1  0  0
22  dd4917b0-af46-4be7-af68-dc31216f003e                 22                   TEXAS DIABETES AND ENDOCRINOLOGY          1      0       1  0  0
23  2c511ac6-2410-422c-972c-3fc9afbdbf05                 23                   RAINIER CLINICAL RESEARCH CENTER          1      0       1  0  0
24  5110c732-134e-4145-a804-9eb4da7d4d29                 24                                STANFORD UNIVERSITY          1      0       1  0  0
25  1ca72b77-8251-4cca-8788-a4d62471fc3d                 25                           UNIVERSITY OF WASHINGTON          1      0       1  0  0
26  4c14cfcd-816d-4b02-9751-3296cc5989be                 26              ICAHN SCHOOL OF MEDICINE AT MT. SINAI          4      0       2  0  0
27  9b2de6c0-256c-4bed-a45f-032cdfa47a3a                 27                       ENDOCRINE RESEARCH SOLUTIONS          1      0       1  0  0
28  0d8bde39-c8ab-48a4-8da6-a165ca2ea71d                 28                    SUNY UPSTATE MEDICAL UNIVERSITY          4      0       4  0  0
29  e5a2b981-d8d3-4e2b-bd80-0eb662af2342                 29                     MASSACHUSETTS GENERAL HOSPITAL          2      0       4  0  0
30  e1f6655b-7020-4253-9d8c-a716b7654405                 30                                       YOGISH KUDVA          0      0       2  0  0
31  fa503b27-431d-4eea-b3c5-b52e329d02af                 31                                       SUZAN BZDICK          4      0       1  0  0
32  f9a5fef1-9afc-4a5c-a4ad-91440147829e                 32                                     RUTH WEINSTOCK          4      0       2  0  0
33  5ab5095d-90ea-4786-bae8-21acc3083a83                 33                                        COREY KUREK          0      0       1  0  0
34  1fabd86f-660d-4ea2-bb29-ce215e356e32                 34                                     MELISSA PUTMAN          2      0       2  0  0
35  a3203481-5a5f-4f53-b4e2-5746406e3645                 35                                         AMY SABEAN          2      0       1  0  0
36  fad021a2-24b4-4be2-b576-4f85fd90e446                 36                                    TYPE 1 DIABETES          0      0       5  0  0
37  4b292758-76b9-4fae-9193-6461e14504f5                 37                                          ROCHESTER          0      0       1  0  0
38  85c34762-f717-4a2b-a7e7-c0b54df3aea2                 38                                           SYRACUSE          4      0       1  0  0
39  4083c7c9-7d70-406a-ad47-edd38692f90d                 39                                             BOSTON          2      0       1  0  0
40  8be220b3-6ae8-4b43-a99f-c891ad7f1a61                 40                                          MINNESOTA          0      0       1  0  0
41  4f2f1709-3ffb-4d86-ac4f-f6bd759f72fb                 41                                      MASSACHUSETTS          2      0       1  0  0
42  ce1f2e83-a01c-4d43-88ae-60a416ffc18b                 42                                           NEW YORK          4      0       2  0  0
43  eef030c7-a036-4e6f-9e09-6c30555b98a6                 43                               CAPILLARY BIOMEDICAL          3      0       6  0  0
44  d7b0344b-0195-4f0f-b348-2110fef1c2e2                 44                                   TANDEM T:SLIM X2          3      0       1  0  0
45  6ea7240e-4499-4fbb-ab0e-b85511766570                 45                                      UNITED STATES          3      0       1  0  0
46  15cc1d82-88da-469d-8ea5-6d8311863ccc                 46                                         START DATE          3      0       1  0  0
47  6287d663-8f61-4b38-84cc-11d8c33399a6                 47                                    COMPLETION DATE          3      0       1  0  0
48  366afc6c-39d3-4d39-9f1a-a9147f79c530                 48                                       PARTICIPANTS          3      0       1  0  0
‚†¶ GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚†á GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ create_final_text_units
                                                  id  human_readable_id  ...                                         entity_ids                                   relationship_ids
0  07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938ab...                  1  ...  [908e379b-e8d1-4dc7-be32-c967a71807a4, a349088...  [31dffae0-69f2-48cb-86be-18604dd5fbca, c08d028...
1  50fcd19011dc02899d75146662bd0110ec7409cbfdb069...                  2  ...  [908e379b-e8d1-4dc7-be32-c967a71807a4, aaa7ca6...  [ee326d38-77e0-452f-ae47-245ae3093c73, bf6db7a...
2  616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686fd...                  3  ...  [fad021a2-24b4-4be2-b576-4f85fd90e446, eef030c...  [0c39c660-33fc-4dc0-8001-d64028e94088, 29c435e...

[3 rows x 7 columns]
‚†á GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îú‚îÄ‚îÄ extract_graph
‚îú‚îÄ‚îÄ compute_communities
‚†è GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îú‚îÄ‚îÄ extract_graph
‚îú‚îÄ‚îÄ compute_communities
‚îú‚îÄ‚îÄ create_final_entities
‚îú‚îÄ‚îÄ create_final_relationships
‚îú‚îÄ‚îÄ create_final_communities
‚îú‚îÄ‚îÄ create_final_nodes
‚îú‚îÄ‚îÄ create_final_text_units
‚îî‚îÄ‚îÄ create_final_community_reports2024-12-15 21:56:48,548 - datashaper.workflow.workflow - INFO - executing verb create_final_community_reports
2024-12-15 21:56:48,548 - create_final_community_reports - DEBUG - create_final_community_reports: Starting execution
2024-12-15 21:56:48,548 - create_final_community_reports - DEBUG - Nodes Input: columns=['id', 'human_readable_id', 'title', 'community', 'level', 'degree', 'x', 'y'] shape=(49, 8)
2024-12-15 21:56:48,548 - create_final_community_reports - DEBUG - Edges Input: columns=['id', 'human_readable_id', 'source', 'target', 'description', 'weight', 'combined_degree', 'text_unit_ids'] shape=(51, 8)
2024-12-15 21:56:48,548 - create_final_community_reports - DEBUG - Entities Input: columns=['id', 'human_readable_id', 'title', 'type', 'description', 'text_unit_ids'] shape=(49, 6)
2024-12-15 21:56:48,548 - create_final_community_reports - DEBUG - Communities Input: columns=['id', 'human_readable_id', 'community', 'parent', 'level', 'title', 'entity_ids', 'relationship_ids', 'text_unit_ids', 'period', 'size'] shape=(5, 11)
2024-12-15 21:56:48,548 - create_final_community_reports - DEBUG - Claims Input: None
2024-12-15 21:56:48,549 - create_final_community_reports - DEBUG - After merging nodes and entities: columns=['id', 'human_readable_id', 'title', 'community', 'level', 'degree', 'x', 'y', 'description'] shape=(49, 9)
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
‚†ô GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îú‚îÄ‚îÄ extract_graph
‚îú‚îÄ‚îÄ compute_communities
‚îú‚îÄ‚îÄ create_final_entities
‚îú‚îÄ‚îÄ create_final_relationships
‚îú‚îÄ‚îÄ create_final_communities
‚îú‚îÄ‚îÄ create_final_nodes
‚îú‚îÄ‚îÄ create_final_text_units
‚îî‚îÄ‚îÄ create_final_community_reports2024-12-15 21:56:48,691 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:48,691 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:56:48,691 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: {
    "title": "Massachusetts General Hospital and Diabetes Research",
    "summary": "The community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the hospital's significant role in clinical research and its potential influence on diabetes treatment and patient outcomes.",
    "findings": [
        {
            "summary": "Massachusetts General Hospital's prominence in healthcare",
            "explanation": "Massachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]"
        },
        {
            "summary": "Melissa Putman's role in diabetes research",
            "explanation": "Melissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]"
        },
        {
            "summary": "Amy Sabean's contribution to clinical trials",
            "explanation": "Amy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]"
        },
        {
            "summary": "The significance of diabetes research at MGH",
            "explanation": "Diabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]"
        },
‚†ô GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îú‚îÄ‚îÄ extract_graph
‚îú‚îÄ‚îÄ compute_communities
‚îú‚îÄ‚îÄ create_final_entities
‚îú‚îÄ‚îÄ create_final_relationships
‚îú‚îÄ‚îÄ create_final_communities
‚îú‚îÄ‚îÄ create_final_nodes
‚îú‚îÄ‚îÄ create_final_text_units
‚îî‚îÄ‚îÄ create_final_community_reports2024-12-15 21:56:48,697 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:48,697 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:56:48,697 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: {
    "title": "Mayo Clinic and Tandem Diabetes Care Community",
    "summary": "This community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the significant implications of diabetes research on public health and the potential for advancements in treatment options.",
    "findings": [
        {
            "summary": "Mayo Clinic's leadership in diabetes research",
            "explanation": "Mayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]"
        },
        {
            "summary": "Tandem Diabetes Care's role as a sponsor",
            "explanation": "Tandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]"
        },
        {
            "summary": "Alayne Lehman's directorial position in clinical trials",
            "explanation": "Alayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]"
        },
        {
            "summary": "Research focus on Type 1 diabetes",
            "explanation": "Type 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]"
        },
        {
            "summary": "Collaboration between entities",
            "explanation": "The relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]"
        }
    ]
}
2024-12-15 21:56:48,697 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:48,697 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:48,697 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 2000, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:56:48,698 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: {
    "title": "Capillary Biomedical Clinical Study",
    "summary": "The community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the potential implications of the clinical study on diabetes management and patient health outcomes.",
    "findings": [
        {
            "summary": "Capillary Biomedical's role in diabetes management",
            "explanation": "Capillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]"
        },
        {
            "summary": "Tandem t:slim X2 insulin pump's significance",
            "explanation": "The Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]"
        },
        {
            "summary": "Geographical scope of the study",
            "explanation": "The clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]"
        },
        {
            "summary": "Timeline of the clinical study",
            "explanation": "The study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]"
        },
        {
            "summary": "Participant enrollment and demographics",
            "explanation": "Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]"
        }
    ]
}
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:48,698 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 2000, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:56:48,698 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: {
    "title": "Extended Wear Insulin Infusion Set Study Community",
    "summary": "The community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the potential implications of the study on diabetes treatment and patient outcomes.",
    "findings": [
        {
            "summary": "Collaboration among multiple research entities",
            "explanation": "The Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)]."
        },
        {
            "summary": "Diverse clinical sites participating in the study",
            "explanation": "The study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)]."
        },
        {
            "summary": "Principal investigators leading the research",
            "explanation": "Several principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)]."
        },
        {
            "summary": "Focus on Type 1 Diabetes management",
            "explanation": "The Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)]."
        },
        {
            "summary": "Potential for significant clinical impact",
            "explanation": "The findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)]."
        }
    ]
}
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:48,698 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 2000, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: Detected community-related prompt
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:56:48,698 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Response Content: {
    "title": "SUNY Upstate Medical University and Diabetes Research Community",
    "summary": "This community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the significant medical research being conducted, which has the potential to influence diabetes treatment and healthcare outcomes.",
    "findings": [
        {
            "summary": "Ruth Weinstock's leadership in diabetes research",
            "explanation": "Dr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]"
        },
        {
            "summary": "SUNY Upstate Medical University's role in medical education and research",
            "explanation": "SUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), Relationships (32, 34)]"
        },
        {
            "summary": "Collaboration with Icahn School of Medicine at Mt. Sinai",
            "explanation": "The Icahn School of Medicine at Mt. Sinai is recognized for its contributions to medical research and education, and its collaboration with SUNY Upstate Medical University enhances the research capabilities of both institutions. This partnership may facilitate access to additional resources, expertise, and clinical trial opportunities, thereby strengthening the overall impact of their research initiatives. [Data: Entities (26), Relationships (27)]"
        },
        {
            "summary": "Suzan Bzdick's role as a contact person",
            "explanation": "Suzan Bzdick, a registered nurse at SUNY Upstate Medical University, serves as a contact person for the diabetes study. Her involvement is essential for coordinating research activities and ensuring effective communication between the research team and participants. The presence of nursing professionals in research settings is critical for patient care and data collection, which can significantly influence the quality and outcomes of clinical studies. [Data: Entities (31), Relationships (32)]"
        },
        {
            "summary": "Syracuse as a key location for medical research",
            "explanation": "Syracuse, New York, is the geographical center of this community, housing SUNY Upstate Medical University and facilitating various medical research initiatives. The city's infrastructure and resources support the university's research activities, making it an important location for advancing medical science. The local community's engagement with the university can also enhance public awareness and support for ongoing research efforts. [Data: Entities (38), Relationships (34)]"
        }
    ]
}
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: history=[]
2024-12-15 21:56:48,698 - OpenAIChatLLM - INFO - OpenAIChatLLM: bypass_cache=False
2024-12-15 21:56:48,699 - OpenAIChatLLM - DEBUG - OpenAIChatLLM: Calling LLM with parameters: {'model': 'gpt-4o-mini', 'frequency_penalty': 0.0, 'max_tokens': 2000, 'n': 1, 'presence_penalty': 0.0, 'temperature': 0.0, 'top_p': 1.0}
2024-12-15 21:56:48,699 - create_final_community_reports - DEBUG - After summarize_communities: columns=['community', 'full_content', 'level', 'rank', 'title', 'rank_explanation', 'summary', 'findings', 'full_content_json'] shape=(5, 9)
2024-12-15 21:56:48,702 - create_final_community_reports - DEBUG - community_reports head:
   community                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              full_content  level  rank                                                            title                                                                                                                                                              rank_explanation                                                                                                                                                                                                                                                                                                                                               summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               full_content_json
0          0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 # Mayo Clinic and Tandem Diabetes Care Community\n\nThis community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.\n\n## Mayo Clinic's leadership in diabetes research\n\nMayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]\n\n## Tandem Diabetes Care's role as a sponsor\n\nTandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]\n\n## Alayne Lehman's directorial position in clinical trials\n\nAlayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]\n\n## Research focus on Type 1 diabetes\n\nType 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]\n\n## Collaboration between entities\n\nThe relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]      0   7.5                   Mayo Clinic and Tandem Diabetes Care Community         The impact severity rating is high due to the significant implications of diabetes research on public health and the potential for advancements in treatment options.  This community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               [{'explanation': 'Mayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]', 'summary': 'Mayo Clinic's leadership in diabetes research'}, {'explanation': 'Tandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]', 'summary': 'Tandem Diabetes Care's role as a sponsor'}, {'explanation': 'Alayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]', 'summary': 'Alayne Lehman's directorial position in clinical trials'}, {'explanation': 'Type 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]', 'summary': 'Research focus on Type 1 diabetes'}, {'explanation': 'The relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]', 'summary': 'Collaboration between entities'}]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  {\n    "title": "Mayo Clinic and Tandem Diabetes Care Community",\n    "summary": "This community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.",\n    "findings": [\n        {\n            "summary": "Mayo Clinic's leadership in diabetes research",\n            "explanation": "Mayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]"\n        },\n        {\n            "summary": "Tandem Diabetes Care's role as a sponsor",\n            "explanation": "Tandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]"\n        },\n        {\n            "summary": "Alayne Lehman's directorial position in clinical trials",\n            "explanation": "Alayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]"\n        },\n        {\n            "summary": "Research focus on Type 1 diabetes",\n            "explanation": "Type 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]"\n        },\n        {\n            "summary": "Collaboration between entities",\n            "explanation": "The relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the significant implications of diabetes research on public health and the potential for advancements in treatment options.",\n    "extra_attributes": {}\n}
1          1                                                                                         # Extended Wear Insulin Infusion Set Study Community\n\nThe community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.\n\n## Collaboration among multiple research entities\n\nThe Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)].\n\n## Diverse clinical sites participating in the study\n\nThe study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)].\n\n## Principal investigators leading the research\n\nSeveral principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)].\n\n## Focus on Type 1 Diabetes management\n\nThe Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)].\n\n## Potential for significant clinical impact\n\nThe findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)].      0   7.5               Extended Wear Insulin Infusion Set Study Community                                                 The impact severity rating is high due to the potential implications of the study on diabetes treatment and patient outcomes.                         The community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.                                                                    [{'explanation': 'The Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)].', 'summary': 'Collaboration among multiple research entities'}, {'explanation': 'The study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)].', 'summary': 'Diverse clinical sites participating in the study'}, {'explanation': 'Several principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)].', 'summary': 'Principal investigators leading the research'}, {'explanation': 'The Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)].', 'summary': 'Focus on Type 1 Diabetes management'}, {'explanation': 'The findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)].', 'summary': 'Potential for significant clinical impact'}]                                                                                                                                  {\n    "title": "Extended Wear Insulin Infusion Set Study Community",\n    "summary": "The community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.",\n    "findings": [\n        {\n            "summary": "Collaboration among multiple research entities",\n            "explanation": "The Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)]."\n        },\n        {\n            "summary": "Diverse clinical sites participating in the study",\n            "explanation": "The study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)]."\n        },\n        {\n            "summary": "Principal investigators leading the research",\n            "explanation": "Several principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)]."\n        },\n        {\n            "summary": "Focus on Type 1 Diabetes management",\n            "explanation": "The Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)]."\n        },\n        {\n            "summary": "Potential for significant clinical impact",\n            "explanation": "The findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)]."\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the potential implications of the study on diabetes treatment and patient outcomes.",\n    "extra_attributes": {}\n}
2          2  # Massachusetts General Hospital and Diabetes Research\n\nThe community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.\n\n## Massachusetts General Hospital's prominence in healthcare\n\nMassachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]\n\n## Melissa Putman's role in diabetes research\n\nMelissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]\n\n## Amy Sabean's contribution to clinical trials\n\nAmy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]\n\n## The significance of diabetes research at MGH\n\nDiabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]\n\n## Boston as a hub for medical research\n\nBoston, where Massachusetts General Hospital is located, is recognized as a major hub for medical research and healthcare innovation. The city's concentration of leading hospitals and research institutions fosters collaboration and knowledge sharing, which is beneficial for advancing medical science. MGH's presence in Boston enhances its ability to attract top talent and funding, further solidifying its role in the healthcare community and its impact on diabetes research. [Data: Entities (39), Relationships (38)]      0   7.5             Massachusetts General Hospital and Diabetes Research        The impact severity rating is high due to the hospital's significant role in clinical research and its potential influence on diabetes treatment and patient outcomes.      The community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.  [{'explanation': 'Massachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]', 'summary': 'Massachusetts General Hospital's prominence in healthcare'}, {'explanation': 'Melissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]', 'summary': 'Melissa Putman's role in diabetes research'}, {'explanation': 'Amy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]', 'summary': 'Amy Sabean's contribution to clinical trials'}, {'explanation': 'Diabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]', 'summary': 'The significance of diabetes research at MGH'}, {'explanation': 'Boston, where Massachusetts General Hospital is located, is recognized as a major hub for medical research and healthcare innovation. The city's concentration of leading hospitals and research institutions fosters collaboration and knowledge sharing, which is beneficial for advancing medical science. MGH's presence in Boston enhances its ability to attract top talent and funding, further solidifying its role in the healthcare community and its impact on diabetes research. [Data: Entities (39), Relationships (38)]', 'summary': 'Boston as a hub for medical research'}]  {\n    "title": "Massachusetts General Hospital and Diabetes Research",\n    "summary": "The community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.",\n    "findings": [\n        {\n            "summary": "Massachusetts General Hospital's prominence in healthcare",\n            "explanation": "Massachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]"\n        },\n        {\n            "summary": "Melissa Putman's role in diabetes research",\n            "explanation": "Melissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]"\n        },\n        {\n            "summary": "Amy Sabean's contribution to clinical trials",\n            "explanation": "Amy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]"\n        },\n        {\n            "summary": "The significance of diabetes research at MGH",\n            "explanation": "Diabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]"\n        },\n        {\n            "summary": "Boston as a hub for medical research",\n            "explanation": "Boston, where Massachusetts General Hospital is located, is recognized as a major hub for medical research and healthcare innovation. The city's concentration of leading hospitals and research institutions fosters collaboration and knowledge sharing, which is beneficial for advancing medical science. MGH's presence in Boston enhances its ability to attract top talent and funding, further solidifying its role in the healthcare community and its impact on diabetes research. [Data: Entities (39), Relationships (38)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the hospital's significant role in clinical research and its potential influence on diabetes treatment and patient outcomes.",\n    "extra_attributes": {}\n}
3          3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           # Capillary Biomedical Clinical Study\n\nThe community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.\n\n## Capillary Biomedical's role in diabetes management\n\nCapillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]\n\n## Tandem t:slim X2 insulin pump's significance\n\nThe Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]\n\n## Geographical scope of the study\n\nThe clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]\n\n## Timeline of the clinical study\n\nThe study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]\n\n## Participant enrollment and demographics\n\nUp to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]      0   7.5                              Capillary Biomedical Clinical Study                                The impact severity rating is high due to the potential implications of the clinical study on diabetes management and patient health outcomes.                                                      The community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.                                                                                                                                                                                                                                                                                                                                                                                                                          [{'explanation': 'Capillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]', 'summary': 'Capillary Biomedical's role in diabetes management'}, {'explanation': 'The Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]', 'summary': 'Tandem t:slim X2 insulin pump's significance'}, {'explanation': 'The clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]', 'summary': 'Geographical scope of the study'}, {'explanation': 'The study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]', 'summary': 'Timeline of the clinical study'}, {'explanation': 'Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]', 'summary': 'Participant enrollment and demographics'}]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   {\n    "title": "Capillary Biomedical Clinical Study",\n    "summary": "The community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.",\n    "findings": [\n        {\n            "summary": "Capillary Biomedical's role in diabetes management",\n            "explanation": "Capillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]"\n        },\n        {\n            "summary": "Tandem t:slim X2 insulin pump's significance",\n            "explanation": "The Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]"\n        },\n        {\n            "summary": "Geographical scope of the study",\n            "explanation": "The clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]"\n        },\n        {\n            "summary": "Timeline of the clinical study",\n            "explanation": "The study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]"\n        },\n        {\n            "summary": "Participant enrollment and demographics",\n            "explanation": "Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the potential implications of the clinical study on diabetes management and patient health outcomes.",\n    "extra_attributes": {}\n}
4          4                                                                                                                                                                                                                                                                                                                                                                                                                                                                             # SUNY Upstate Medical University and Diabetes Research Community\n\nThis community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.\n\n## Ruth Weinstock's leadership in diabetes research\n\nDr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]\n\n## SUNY Upstate Medical University's role in medical education and research\n\nSUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), Relationships (32, 34)]\n\n## Collaboration with Icahn School of Medicine at Mt. Sinai\n\nThe Icahn School of Medicine at Mt. Sinai is recognized for its contributions to medical research and education, and its collaboration with SUNY Upstate Medical University enhances the research capabilities of both institutions. This partnership may facilitate access to additional resources, expertise, and clinical trial opportunities, thereby strengthening the overall impact of their research initiatives. [Data: Entities (26), Relationships (27)]\n\n## Suzan Bzdick's role as a contact person\n\nSuzan Bzdick, a registered nurse at SUNY Upstate Medical University, serves as a contact person for the diabetes study. Her involvement is essential for coordinating research activities and ensuring effective communication between the research team and participants. The presence of nursing professionals in research settings is critical for patient care and data collection, which can significantly influence the quality and outcomes of clinical studies. [Data: Entities (31), Relationships (32)]\n\n## Syracuse as a key location for medical research\n\nSyracuse, New York, is the geographical center of this community, housing SUNY Upstate Medical University and facilitating various medical research initiatives. The city's infrastructure and resources support the university's research activities, making it an important location for advancing medical science. The local community's engagement with the university can also enhance public awareness and support for ongoing research efforts. [Data: Entities (38), Relationships (34)]      0   7.5  SUNY Upstate Medical University and Diabetes Research Community  The impact severity rating is high due to the significant medical research being conducted, which has the potential to influence diabetes treatment and healthcare outcomes.        This community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [{'explanation': 'Dr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]', 'summary': 'Ruth Weinstock's leadership in diabetes research'}, {'explanation': 'SUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), Relationships (32, 34)]', 'summary': 'SUNY Upstate Medical University's role in medical education and research'}, {'explanation': 'The Icahn School of Medicine at Mt. Sinai is recognized for its contributions to medical research and education, and its collaboration with SUNY Upstate Medical University enhances the research capabilities of both institutions. This partnership may facilitate access to additional resources, expertise, and clinical trial opportunities, thereby strengthening the overall impact of their research initiatives. [Data: Entities (26), Relationships (27)]', 'summary': 'Collaboration with Icahn School of Medicine at Mt. Sinai'}, {'explanation': 'Suzan Bzdick, a registered nurse at SUNY Upstate Medical University, serves as a contact person for the diabetes study. Her involvement is essential for coordinating research activities and ensuring effective communication between the research team and participants. The presence of nursing professionals in research settings is critical for patient care and data collection, which can significantly influence the quality and outcomes of clinical studies. [Data: Entities (31), Relationships (32)]', 'summary': 'Suzan Bzdick's role as a contact person'}, {'explanation': 'Syracuse, New York, is the geographical center of this community, housing SUNY Upstate Medical University and facilitating various medical research initiatives. The city's infrastructure and resources support the university's research activities, making it an important location for advancing medical science. The local community's engagement with the university can also enhance public awareness and support for ongoing research efforts. [Data: Entities (38), Relationships (34)]', 'summary': 'Syracuse as a key location for medical research'}]                                                                                                                                                                                                                                                                                                                                                                                                                                                                       {\n    "title": "SUNY Upstate Medical University and Diabetes Research Community",\n    "summary": "This community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.",\n    "findings": [\n        {\n            "summary": "Ruth Weinstock's leadership in diabetes research",\n            "explanation": "Dr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]"\n        },\n        {\n            "summary": "SUNY Upstate Medical University's role in medical education and research",\n            "explanation": "SUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), Relationships (32, 34)]"\n        },\n        {\n            "summary": "Collaboration with Icahn School of Medicine at Mt. Sinai",\n            "explanation": "The Icahn School of Medicine at Mt. Sinai is recognized for its contributions to medical research and education, and its collaboration with SUNY Upstate Medical University enhances the research capabilities of both institutions. This partnership may facilitate access to additional resources, expertise, and clinical trial opportunities, thereby strengthening the overall impact of their research initiatives. [Data: Entities (26), Relationships (27)]"\n        },\n        {\n            "summary": "Suzan Bzdick's role as a contact person",\n            "explanation": "Suzan Bzdick, a registered nurse at SUNY Upstate Medical University, serves as a contact person for the diabetes study. Her involvement is essential for coordinating research activities and ensuring effective communication between the research team and participants. The presence of nursing professionals in research settings is critical for patient care and data collection, which can significantly influence the quality and outcomes of clinical studies. [Data: Entities (31), Relationships (32)]"\n        },\n        {\n            "summary": "Syracuse as a key location for medical research",\n            "explanation": "Syracuse, New York, is the geographical center of this community, housing SUNY Upstate Medical University and facilitating various medical research initiatives. The city's infrastructure and resources support the university's research activities, making it an important location for advancing medical science. The local community's engagement with the university can also enhance public awareness and support for ongoing research efforts. [Data: Entities (38), Relationships (34)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the significant medical research being conducted, which has the potential to influence diabetes treatment and healthcare outcomes.",\n    "extra_attributes": {}\n}
2024-12-15 21:56:48,703 - create_final_community_reports - DEBUG - 'community' column found, proceeding...
2024-12-15 21:56:48,704 - create_final_community_reports - DEBUG - After merging with communities: columns=['community', 'full_content', 'level', 'rank', 'title', 'rank_explanation', 'summary', 'findings', 'full_content_json', 'human_readable_id', 'id', 'parent', 'size', 'period'] shape=(5, 14)
2024-12-15 21:56:48,707 - create_final_community_reports - DEBUG - Final merged head:
   community                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              full_content  level  rank                                                            title                                                                                                                                                              rank_explanation                                                                                                                                                                                                                                                                                                                                               summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               full_content_json  human_readable_id                                id  parent  size      period
0          0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 # Mayo Clinic and Tandem Diabetes Care Community\n\nThis community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.\n\n## Mayo Clinic's leadership in diabetes research\n\nMayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]\n\n## Tandem Diabetes Care's role as a sponsor\n\nTandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]\n\n## Alayne Lehman's directorial position in clinical trials\n\nAlayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]\n\n## Research focus on Type 1 diabetes\n\nType 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]\n\n## Collaboration between entities\n\nThe relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]      0   7.5                   Mayo Clinic and Tandem Diabetes Care Community         The impact severity rating is high due to the significant implications of diabetes research on public health and the potential for advancements in treatment options.  This community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               [{'explanation': 'Mayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]', 'summary': 'Mayo Clinic's leadership in diabetes research'}, {'explanation': 'Tandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]', 'summary': 'Tandem Diabetes Care's role as a sponsor'}, {'explanation': 'Alayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]', 'summary': 'Alayne Lehman's directorial position in clinical trials'}, {'explanation': 'Type 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]', 'summary': 'Research focus on Type 1 diabetes'}, {'explanation': 'The relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]', 'summary': 'Collaboration between entities'}]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  {\n    "title": "Mayo Clinic and Tandem Diabetes Care Community",\n    "summary": "This community centers around the Mayo Clinic and Tandem Diabetes Care, Inc., both of which are involved in clinical research related to Type 1 diabetes and the Extended Wear Insulin Infusion Set. The entities are interconnected through their participation in clinical trials and research initiatives aimed at improving diabetes management.",\n    "findings": [\n        {\n            "summary": "Mayo Clinic's leadership in diabetes research",\n            "explanation": "Mayo Clinic is a leading medical center recognized for its excellence in clinical research and patient care, particularly in the field of diabetes. The clinic is currently involved in the Extended Wear Insulin Infusion Set study, which aims to enhance insulin delivery for individuals with Type 1 diabetes. This involvement positions Mayo Clinic as a pivotal entity in advancing diabetes treatment options, potentially impacting a large patient population. [Data: Entities (15), Relationships (15)]"\n        },\n        {\n            "summary": "Tandem Diabetes Care's role as a sponsor",\n            "explanation": "Tandem Diabetes Care, Inc. serves as the lead sponsor for the Extended Wear Insulin Infusion Set study, highlighting its commitment to developing innovative insulin delivery products. This sponsorship indicates the company's active role in shaping the future of diabetes management, which could lead to significant improvements in the quality of life for individuals with Type 1 diabetes. [Data: Entities (0), Relationships (0)]"\n        },\n        {\n            "summary": "Alayne Lehman's directorial position in clinical trials",\n            "explanation": "Alayne Lehman, as the study director for the Extended Wear Insulin Infusion Set study at Mayo Clinic, plays a crucial role in overseeing the clinical trials. Her expertise and leadership are essential for ensuring the study's integrity and success, which could lead to groundbreaking advancements in diabetes treatment. [Data: Entities (2), Relationships (2)]"\n        },\n        {\n            "summary": "Research focus on Type 1 diabetes",\n            "explanation": "Type 1 diabetes is a chronic condition that requires continuous management and innovative research to improve treatment options. The community's focus on this condition through clinical trials, particularly the Extended Wear Insulin Infusion Set, underscores the importance of ongoing research in finding effective solutions for individuals living with this disease. [Data: Entities (36), Relationships (41)]"\n        },\n        {\n            "summary": "Collaboration between entities",\n            "explanation": "The relationships between Mayo Clinic, Tandem Diabetes Care, and the clinical trials indicate a collaborative effort to advance diabetes research. This collaboration is vital for pooling resources, expertise, and knowledge, which can lead to more effective treatment options and improved patient outcomes. [Data: Relationships (15, 0, 2)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the significant implications of diabetes research on public health and the potential for advancements in treatment options.",\n    "extra_attributes": {}\n}                  0  8bd2fd17dcc84ed2a0cf86c69124ad40      -1     8  2024-12-15
1          1                                                                                         # Extended Wear Insulin Infusion Set Study Community\n\nThe community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.\n\n## Collaboration among multiple research entities\n\nThe Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)].\n\n## Diverse clinical sites participating in the study\n\nThe study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)].\n\n## Principal investigators leading the research\n\nSeveral principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)].\n\n## Focus on Type 1 Diabetes management\n\nThe Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)].\n\n## Potential for significant clinical impact\n\nThe findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)].      0   7.5               Extended Wear Insulin Infusion Set Study Community                                                 The impact severity rating is high due to the potential implications of the study on diabetes treatment and patient outcomes.                         The community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.                                                                    [{'explanation': 'The Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)].', 'summary': 'Collaboration among multiple research entities'}, {'explanation': 'The study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)].', 'summary': 'Diverse clinical sites participating in the study'}, {'explanation': 'Several principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)].', 'summary': 'Principal investigators leading the research'}, {'explanation': 'The Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)].', 'summary': 'Focus on Type 1 Diabetes management'}, {'explanation': 'The findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)].', 'summary': 'Potential for significant clinical impact'}]                                                                                                                                  {\n    "title": "Extended Wear Insulin Infusion Set Study Community",\n    "summary": "The community is centered around the Extended Wear Insulin Infusion Set (EWIS) study, involving multiple clinical sites and principal investigators across the United States. Key entities include various hospitals and research centers collaborating on this investigational study aimed at improving diabetes management.",\n    "findings": [\n        {\n            "summary": "Collaboration among multiple research entities",\n            "explanation": "The Extended Wear Insulin Infusion Set study involves a wide range of collaborators, including hospitals and research institutions. This collaboration enhances the study's credibility and reach, allowing for diverse patient populations and comprehensive data collection. The Jaeb Center for Health Research is a key collaborator, working alongside principal investigators from various clinical sites such as Henry Ford Health System and Stanford University. This network of entities is crucial for the successful execution of the study and the potential advancements in diabetes care [Data: Entities (1, 16); Relationships (1, 16)]."\n        },\n        {\n            "summary": "Diverse clinical sites participating in the study",\n            "explanation": "The study is being conducted at numerous clinical sites across the United States, including well-known institutions like the International Diabetes Center and Northwestern University. Each site contributes unique expertise and resources, which can lead to more robust findings. The involvement of multiple sites also allows for a broader demographic representation, which is essential for the generalizability of the study results. This diversity is a significant strength of the research initiative [Data: Entities (17, 19, 21, 24, 25); Relationships (17, 19, 21, 24, 25)]."\n        },\n        {\n            "summary": "Principal investigators leading the research",\n            "explanation": "Several principal investigators are leading the study at different clinical sites, including John C Reed at Endocrine Research Solutions and Rayhan Lal at Stanford University. Their expertise in diabetes research is vital for the study's design and implementation. The leadership of these experienced professionals is expected to enhance the quality of the research and ensure adherence to ethical standards. Their roles are critical in guiding the study towards achieving its objectives [Data: Entities (3, 4, 6, 10, 12); Relationships (3, 4, 6, 10, 12)]."\n        },\n        {\n            "summary": "Focus on Type 1 Diabetes management",\n            "explanation": "The Extended Wear Insulin Infusion Set study specifically targets individuals with Type 1 Diabetes, aiming to assess the efficacy of the EWIS in improving insulin delivery and patient outcomes. This focus is particularly important given the challenges faced by Type 1 Diabetes patients in managing their condition. The study's outcomes could lead to significant advancements in treatment protocols and improve the quality of life for many patients [Data: Entities (16); Relationships (16)]."\n        },\n        {\n            "summary": "Potential for significant clinical impact",\n            "explanation": "The findings from the Extended Wear Insulin Infusion Set study have the potential to influence clinical practices significantly. If successful, the study could lead to new standards in diabetes management, particularly in insulin delivery methods. This could not only improve patient outcomes but also reduce healthcare costs associated with diabetes complications. The implications of this research extend beyond the immediate study participants, potentially affecting a larger population of individuals with diabetes [Data: Relationships (16)]."\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the potential implications of the study on diabetes treatment and patient outcomes.",\n    "extra_attributes": {}\n}                  1  6ed78d801b0c48feb0ae8506279c3941      -1    24  2024-12-15
2          2  # Massachusetts General Hospital and Diabetes Research\n\nThe community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.\n\n## Massachusetts General Hospital's prominence in healthcare\n\nMassachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]\n\n## Melissa Putman's role in diabetes research\n\nMelissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]\n\n## Amy Sabean's contribution to clinical trials\n\nAmy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]\n\n## The significance of diabetes research at MGH\n\nDiabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]\n\n## Boston as a hub for medical research\n\nBoston, where Massachusetts General Hospital is located, is recognized as a major hub for medical research and healthcare innovation. The city's concentration of leading hospitals and research institutions fosters collaboration and knowledge sharing, which is beneficial for advancing medical science. MGH's presence in Boston enhances its ability to attract top talent and funding, further solidifying its role in the healthcare community and its impact on diabetes research. [Data: Entities (39), Relationships (38)]      0   7.5             Massachusetts General Hospital and Diabetes Research        The impact severity rating is high due to the hospital's significant role in clinical research and its potential influence on diabetes treatment and patient outcomes.      The community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.  [{'explanation': 'Massachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]', 'summary': 'Massachusetts General Hospital's prominence in healthcare'}, {'explanation': 'Melissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]', 'summary': 'Melissa Putman's role in diabetes research'}, {'explanation': 'Amy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]', 'summary': 'Amy Sabean's contribution to clinical trials'}, {'explanation': 'Diabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]', 'summary': 'The significance of diabetes research at MGH'}, {'explanation': 'Boston, where Massachusetts General Hospital is located, is recognized as a major hub for medical research and healthcare innovation. The city's concentration of leading hospitals and research institutions fosters collaboration and knowledge sharing, which is beneficial for advancing medical science. MGH's presence in Boston enhances its ability to attract top talent and funding, further solidifying its role in the healthcare community and its impact on diabetes research. [Data: Entities (39), Relationships (38)]', 'summary': 'Boston as a hub for medical research'}]  {\n    "title": "Massachusetts General Hospital and Diabetes Research",\n    "summary": "The community is centered around Massachusetts General Hospital, a major teaching hospital in Boston, where key entities such as Melissa Putman and Amy Sabean are involved in diabetes research and clinical trials. Their relationships highlight the hospital's role in advancing medical research and patient care in the field of diabetes.",\n    "findings": [\n        {\n            "summary": "Massachusetts General Hospital's prominence in healthcare",\n            "explanation": "Massachusetts General Hospital (MGH) is a leading institution in Boston, known for its extensive involvement in clinical research and patient care. As a major teaching hospital, MGH plays a crucial role in training healthcare professionals and conducting innovative research. Its reputation and resources position it as a key player in the healthcare landscape, particularly in the field of diabetes research. The hospital's relationships with researchers and clinical trial coordinators further emphasize its central role in advancing medical knowledge and improving patient care. [Data: Entities (29), Relationships (36, 38, 39)]"\n        },\n        {\n            "summary": "Melissa Putman's role in diabetes research",\n            "explanation": "Melissa Putman is a principal investigator at Massachusetts General Hospital, specifically involved in diabetes research. Her work is critical in understanding and developing new treatments for diabetes, which affects millions of people worldwide. The relationship between Putman and MGH highlights the hospital's commitment to addressing chronic health issues through research. Her involvement in diabetes research signifies the hospital's focus on impactful medical studies that can lead to significant advancements in treatment options. [Data: Entities (34), Relationships (44, 36)]"\n        },\n        {\n            "summary": "Amy Sabean's contribution to clinical trials",\n            "explanation": "Amy Sabean serves as a contact person for clinical trials at Massachusetts General Hospital, facilitating the connection between researchers and participants. Her role is vital in ensuring that clinical trials run smoothly and effectively, which is essential for the advancement of medical research. The relationship between Sabean and MGH underscores the importance of coordination in clinical research, particularly in trials related to diabetes, where patient participation is crucial for gathering data and testing new therapies. [Data: Entities (35), Relationships (37)]"\n        },\n        {\n            "summary": "The significance of diabetes research at MGH",\n            "explanation": "Diabetes research at Massachusetts General Hospital is a focal point of the institution's medical research efforts. The hospital's involvement in this area not only contributes to scientific knowledge but also has the potential to improve treatment protocols and patient outcomes. The collaborative efforts of researchers like Melissa Putman and the support from clinical trial coordinators like Amy Sabean enhance the hospital's capacity to conduct impactful studies that can lead to breakthroughs in diabetes care. [Data: Relationships (44, 36)]"\n        },\n        {\n            "summary": "Boston as a hub for medical research",\n            "explanation": "Boston, where Massachusetts General Hospital is located, is recognized as a major hub for medical research and healthcare innovation. The city's concentration of leading hospitals and research institutions fosters collaboration and knowledge sharing, which is beneficial for advancing medical science. MGH's presence in Boston enhances its ability to attract top talent and funding, further solidifying its role in the healthcare community and its impact on diabetes research. [Data: Entities (39), Relationships (38)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the hospital's significant role in clinical research and its potential influence on diabetes treatment and patient outcomes.",\n    "extra_attributes": {}\n}                  2  27e59eec28ae45a78d6ca474cdbdaf29      -1     5  2024-12-15
3          3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           # Capillary Biomedical Clinical Study\n\nThe community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.\n\n## Capillary Biomedical's role in diabetes management\n\nCapillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]\n\n## Tandem t:slim X2 insulin pump's significance\n\nThe Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]\n\n## Geographical scope of the study\n\nThe clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]\n\n## Timeline of the clinical study\n\nThe study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]\n\n## Participant enrollment and demographics\n\nUp to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]      0   7.5                              Capillary Biomedical Clinical Study                                The impact severity rating is high due to the potential implications of the clinical study on diabetes management and patient health outcomes.                                                      The community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.                                                                                                                                                                                                                                                                                                                                                                                                                          [{'explanation': 'Capillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]', 'summary': 'Capillary Biomedical's role in diabetes management'}, {'explanation': 'The Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]', 'summary': 'Tandem t:slim X2 insulin pump's significance'}, {'explanation': 'The clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]', 'summary': 'Geographical scope of the study'}, {'explanation': 'The study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]', 'summary': 'Timeline of the clinical study'}, {'explanation': 'Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]', 'summary': 'Participant enrollment and demographics'}]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   {\n    "title": "Capillary Biomedical Clinical Study",\n    "summary": "The community centers around Capillary Biomedical, which is conducting a clinical study involving the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. The study will take place in the United States, enrolling up to 300 participants, with a defined start and completion date.",\n    "findings": [\n        {\n            "summary": "Capillary Biomedical's role in diabetes management",\n            "explanation": "Capillary Biomedical is the primary organization conducting a clinical study that aims to evaluate the effectiveness of the Tandem t:slim X2 insulin pump for adults with Type 1 diabetes. This study is significant as it could lead to advancements in diabetes management, potentially improving the quality of life for many patients. The organization is responsible for overseeing the study's design, implementation, and analysis, which underscores its critical role in the healthcare landscape. [Data: Entities (43), Relationships (45)]"\n        },\n        {\n            "summary": "Tandem t:slim X2 insulin pump's significance",\n            "explanation": "The Tandem t:slim X2 insulin pump is a key component of the clinical study, equipped with Control-IQ technology and continuous Glucose Monitoring (CGM). This technology represents a significant advancement in diabetes care, allowing for more precise insulin delivery and better glucose control. The study's focus on this device highlights its potential impact on treatment protocols and patient outcomes, making it a focal point of the research. [Data: Entities (44), Relationships (45)]"\n        },\n        {\n            "summary": "Geographical scope of the study",\n            "explanation": "The clinical study will take place in the United States, which allows for a diverse participant pool from various locations. This geographical scope is crucial for the study's validity, as it can capture a wide range of demographic and health-related variables. The inclusion of participants from different backgrounds may enhance the generalizability of the study's findings, making it relevant to a broader population. [Data: Entities (45), Relationships (47)]"\n        },\n        {\n            "summary": "Timeline of the clinical study",\n            "explanation": "The study is set to begin on March 7, 2024, and is expected to be completed by January 15, 2025. This timeline is critical for stakeholders, including participants, healthcare providers, and investors, as it outlines the duration of the study and the expected milestones. The defined start and completion dates also indicate a structured approach to data collection and analysis, which is essential for the integrity of the research. [Data: Entities (46, 47), Relationships (48, 49)]"\n        },\n        {\n            "summary": "Participant enrollment and demographics",\n            "explanation": "Up to 300 participants aged 18-80 will be enrolled in the study across various investigational centers. This demographic range is significant as it encompasses a large segment of the adult population affected by Type 1 diabetes. The study's design to include a diverse participant base is likely to yield comprehensive data on the insulin pump's effectiveness across different age groups and health statuses, which is vital for developing tailored treatment strategies. [Data: Entities (48), Relationships (50)]"\n        }\n    ],\n    "rating": 7.5,\n    "rating_explanation": "The impact severity rating is high due to the potential implications of the clinical study on diabetes management and patient health outcomes.",\n    "extra_attributes": {}\n}                  3  430f19d6c5b5423b9b083d84d0e516fb      -1     6  2024-12-15
4          4                                                                                                                                                                                                                                                                                                                                                                                                                                                                             # SUNY Upstate Medical University and Diabetes Research Community\n\nThis community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.\n\n## Ruth Weinstock's leadership in diabetes research\n\nDr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]\n\n## SUNY Upstate Medical University's role in medical education and research\n\nSUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), Relationships (32, 34)]\n\n## Collaboration with Icahn School of Medicine at Mt. Sinai\n\nThe Icahn School of Medicine at Mt. Sinai is recognized for its contributions to medical research and education, and its collaboration with SUNY Upstate Medical University enhances the research capabilities of both institutions. This partnership may facilitate access to additional resources, expertise, and clinical trial opportunities, thereby strengthening the overall impact of their research initiatives. [Data: Entities (26), Relationships (27)]\n\n## Suzan Bzdick's role as a contact person\n\nSuzan Bzdick, a registered nurse at SUNY Upstate Medical University, serves as a contact person for the diabetes study. Her involvement is essential for coordinating research activities and ensuring effective communication between the research team and participants. The presence of nursing professionals in research settings is critical for patient care and data collection, which can significantly influence the quality and outcomes of clinical studies. [Data: Entities (31), Relationships (32)]\n\n## Syracuse as a key location for medical research\n\nSyracuse, New York, is the geographical center of this community, housing SUNY Upstate Medical University and facilitating various medical research initiatives. The city's infrastructure and resources support the university's research activities, making it an important location for advancing medical science. The local community's engagement with the university can also enhance public awareness and support for ongoing research efforts. [Data: Entities (38), Relationships (34)]      0   7.5  SUNY Upstate Medical University and Diabetes Research Community  The impact severity rating is high due to the significant medical research being conducted, which has the potential to influence diabetes treatment and healthcare outcomes.        This community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [{'explanation': 'Dr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]', 'summary': 'Ruth Weinstock's leadership in diabetes research'}, {'explanation': 'SUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), Relationships (32, 34)]', 'summary': 'SUNY Upstate Medical University's role in medical education and research'}, {'explanation': 'The Icahn School of Medicine at Mt. Sinai is recognized for its contributions to medical research and education, and its collaboration with SUNY Upstate Medical University enhances the research capabilities of both institutions. This partnership may facilitate access to additional resources, expertise, and clinical trial opportunities, thereby strengthening the overall impact of their research initiatives. [Data: Entities (26), Relationships (27)]', 'summary': 'Collaboration with Icahn School of Medicine at Mt. Sinai'}, {'explanation': 'Suzan Bzdick, a registered nurse at SUNY Upstate Medical University, serves as a contact person for the diabetes study. Her involvement is essential for coordinating research activities and ensuring effective communication between the research team and participants. The presence of nursing professionals in research settings is critical for patient care and data collection, which can significantly influence the quality and outcomes of clinical studies. [Data: Entities (31), Relationships (32)]', 'summary': 'Suzan Bzdick's role as a contact person'}, {'explanation': 'Syracuse, New York, is the geographical center of this community, housing SUNY Upstate Medical University and facilitating various medical research initiatives. The city's infrastructure and resources support the university's research activities, making it an important location for advancing medical science. The local community's engagement with the university can also enhance public awareness and support for ongoing research efforts. [Data: Entities (38), Relationships (34)]', 'summary': 'Syracuse as a key location for medical research'}]                                                                                                                                                                                                                                                                                                                                                                                                                                                                       {\n    "title": "SUNY Upstate Medical University and Diabetes Research Community",\n    "summary": "This community is centered around SUNY Upstate Medical University, which is engaged in diabetes research led by Dr. Ruth Weinstock. The community includes key entities such as the Icahn School of Medicine at Mt. Sinai and registered nurse Suzan Bzdick, highlighting a collaborative effort in medical research within the Syracuse area.",\n    "findings": [\n        {\n            "summary": "Ruth Weinstock's leadership in diabetes research",\n            "explanation": "Dr. Ruth Weinstock is a principal investigator at SUNY Upstate Medical University, focusing on Type 1 diabetes research. Her role is crucial as she leads studies that could advance understanding and treatment of this chronic condition. The research conducted under her guidance is likely to have a substantial impact on diabetes management and patient care, potentially influencing clinical practices and health policies. [Data: Entities (32), Relationships (43)]"\n        },\n        {\n            "summary": "SUNY Upstate Medical University's role in medical education and research",\n            "explanation": "SUNY Upstate Medical University is a prominent institution in Syracuse, New York, dedicated to medical education and research. It serves as a hub for various medical studies, including diabetes research, and plays a vital role in training healthcare professionals. The university's commitment to advancing medical knowledge and improving patient outcomes positions it as a key player in the healthcare landscape. [Data: Entities (28), RelaüöÄ create_final_community_reports
                                 id  human_readable_id  community  parent  ...                                           findings                                  full_content_json      period size
0  8bd2fd17dcc84ed2a0cf86c69124ad40                  0          0      -1  ...  [{'explanation': 'Mayo Clinic is a leading med...  {\n    "title": "Mayo Clinic and Tandem Diabet...  2024-12-15    8
1  6ed78d801b0c48feb0ae8506279c3941                  1          1      -1  ...  [{'explanation': 'The Extended Wear Insulin In...  {\n    "title": "Extended Wear Insulin Infusio...  2024-12-15   24
2  27e59eec28ae45a78d6ca474cdbdaf29                  2          2      -1  ...  [{'explanation': 'Massachusetts General Hospit...  {\n    "title": "Massachusetts General Hospita...  2024-12-15    5
3  430f19d6c5b5423b9b083d84d0e516fb                  3          3      -1  ...  [{'explanation': 'Capillary Biomedical is the ...  {\n    "title": "Capillary Biomedical Clinical...  2024-12-15    6
4  ebd8f76320cf45b2b4bb5dbbbed5ccb9                  4          4      -1  ...  [{'explanation': 'Dr. Ruth Weinstock is a prin...  {\n    "title": "SUNY Upstate Medical Universi...  2024-12-15    6

[5 rows x 14 columns]
‚†π GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îú‚îÄ‚îÄ extract_graph
‚îú‚îÄ‚îÄ compute_communities
‚îú‚îÄ‚îÄ create_final_entities
‚†º GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚†á GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚†è GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
üöÄ generate_text_embeddings
Empty DataFrame
Columns: []
Index: []
‚†ã GraphRAG Indexer 
Index building completed.
‚†ã GraphRAG Indexer 
‚îú‚îÄ‚îÄ Loading Input (text) - 1 files loaded (0 filtered) ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ 100% 0:00:00 0:00:00
‚îú‚îÄ‚îÄ create_base_text_units
‚îú‚îÄ‚îÄ create_final_documents
‚îú‚îÄ‚îÄ extract_graph
‚îú‚îÄ‚îÄ compute_communities
‚îú‚îÄ‚îÄ create_final_entities
‚îú‚îÄ‚îÄ create_final_relationships
‚îú‚îÄ‚îÄ create_final_communities
‚îú‚îÄ‚îÄ create_final_nodes
‚îú‚îÄ‚îÄ create_final_text_units
‚îú‚îÄ‚îÄ create_final_community_reports
‚îî‚îÄ‚îÄ generate_text_embeddings2024-12-15 21:56:49,392 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_base_text_units', result=Empty DataFrame
Columns: []
Index: [], errors=None)
2024-12-15 21:56:49,394 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_documents', result=                                                  id  human_readable_id                    title                                               text                                      text_unit_ids
0  3e483c6a024c09ea2f5d53d99bb05cc1da5c58382ecb1d...                  1  ctgov_fullcontent_1.txt  # NCTId\nNCT06273124\n# study_url\nhttps://www...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a..., errors=None)
2024-12-15 21:56:49,394 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='extract_graph', result=Empty DataFrame
Columns: []
Index: [], errors=None)
2024-12-15 21:56:49,394 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='compute_communities', result=Empty DataFrame
Columns: []
Index: [], errors=None)
2024-12-15 21:56:49,402 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_entities', result=                                      id  human_readable_id                                              title          type                                        description                                      text_unit_ids
0   908e379b-e8d1-4dc7-be32-c967a71807a4                  0                         TANDEM DIABETES CARE, INC.  ORGANIZATION  Tandem Diabetes Care, Inc. is a company dedica...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
1   a3490882-513f-4c85-b1b0-65bcf79d6aa3                  1                    JAEB CENTER FOR HEALTH RESEARCH  ORGANIZATION  Jaeb Center for Health Research is a collabora...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
2   aaa7ca6d-608f-4ee7-9bbf-a406980ccc29                  2                                      ALAYNE LEHMAN        PERSON  Alayne Lehman is a registered nurse and serves...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
3   b6c1ffe7-36d4-4acd-be13-2c18529effe0                  3                                        JOHN C REED        PERSON  John C Reed is the principal investigator at E...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
4   6a0357bd-1753-4eb9-9616-d98477592dbc                  4                                      DAVIDA KRUGER        PERSON  Davida Kruger is a principal investigator at H...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
5   b1cd393b-64cc-407e-bddf-6afeac5c3ba4                  5                                    BRITTANY DENNIS        PERSON  Brittany Dennis is a contact for Hoag Memorial...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
6   03b2b5e0-e0fb-4d2c-8182-8c9d9c2eaa2a                  6                                 RICHARD BERGENSTAL        PERSON  Richard Bergenstal is a principal investigator...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
7   f1cb7990-08e3-45fe-977c-7e28c5528280                  7                                     SAMANTHA LANGE        PERSON  Samantha Lange is a contact for Barbara Davis ...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
8   7f6ba670-2db8-448e-b1c5-0edf2f578907                  8                                      GRAZIA ALEPPO        PERSON  Grazia Aleppo is a principal investigator at N...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
9   8ddfb07e-7b56-45db-8f49-971fc7d5d2b4                  9                                       WYATT LARSON        PERSON  Wyatt Larson is a contact for Rocky Mountain C...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
10  09dd480a-3dd8-499b-9390-9f287bf5e66f                 10                                          JEAN CHEN        PERSON  Jean Chen is a principal investigator at Texas...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
11  18139ae3-a441-48e1-b6c9-fc1be7282717                 11                                      TINA MITCHELL        PERSON  Tina Mitchell is a contact for Rainier Clinica...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
12  0c766ec0-0059-4e3c-b1b4-42b637061769                 12                                         RAYHAN LAL        PERSON  Rayhan Lal is a principal investigator at Stan...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
13  157d2eaa-7726-4f18-8435-cf93e1686f7b                 13                                      DORI KHAKPOUR        PERSON  Dori Khakpour is a contact for University of W...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
14  32079101-61a5-4cbd-9161-e8ed225c52e9                 14                                   CAMILLA LEVISTER        PERSON  Camilla Levister is a principal investigator a...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
15  7e874f82-f87c-48e4-a1ab-2e20497e8a81                 15                                        MAYO CLINIC  ORGANIZATION  Mayo Clinic is a renowned medical center locat...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
16  68d0c128-4506-4e70-b6bb-260ef7460b75                 16                 EXTENDED WEAR INSULIN INFUSION SET         EVENT  The Extended Wear Insulin Infusion Set (EWIS) ...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
17  bbbe945a-db9e-4cb6-8325-c4cfa11b27be                 17                           HENRY FORD HEALTH SYSTEM  ORGANIZATION  Henry Ford Health System is a clinical site in...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
18  b9f31ada-5ca3-4b46-8870-d8fd94edf05c                 18                HOAG MEMORIAL HOSPITAL PRESBYTERIAN  ORGANIZATION  Hoag Memorial Hospital Presbyterian is a clini...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
19  6bb5b0d1-c24c-4119-bce1-5be518c99817                 19  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...  ORGANIZATION  International Diabetes Center - HealthPartners...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
20  1e6edc99-41d4-49d6-a619-49c3a31305aa                 20                               BARBARA DAVIS CENTER  ORGANIZATION  Barbara Davis Center is a clinical site involv...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
21  a60f7332-09fa-4228-8b59-4ba3c543d993                 21                            NORTHWESTERN UNIVERSITY  ORGANIZATION  Northwestern University is a clinical site inv...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
22  dd4917b0-af46-4be7-af68-dc31216f003e                 22                   TEXAS DIABETES AND ENDOCRINOLOGY  ORGANIZATION  Texas Diabetes and Endocrinology is a clinical...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
23  2c511ac6-2410-422c-972c-3fc9afbdbf05                 23                   RAINIER CLINICAL RESEARCH CENTER  ORGANIZATION  Rainier Clinical Research Center is a clinical...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
24  5110c732-134e-4145-a804-9eb4da7d4d29                 24                                STANFORD UNIVERSITY  ORGANIZATION  Stanford University is a clinical site involve...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
25  1ca72b77-8251-4cca-8788-a4d62471fc3d                 25                           UNIVERSITY OF WASHINGTON  ORGANIZATION  University of Washington is a clinical site in...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
26  4c14cfcd-816d-4b02-9751-3296cc5989be                 26              ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ORGANIZATION  The Icahn School of Medicine at Mt. Sinai is a...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
27  9b2de6c0-256c-4bed-a45f-032cdfa47a3a                 27                       ENDOCRINE RESEARCH SOLUTIONS                                                                   [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
28  0d8bde39-c8ab-48a4-8da6-a165ca2ea71d                 28                    SUNY UPSTATE MEDICAL UNIVERSITY  ORGANIZATION  SUNY Upstate Medical University is a public me...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
29  e5a2b981-d8d3-4e2b-bd80-0eb662af2342                 29                     MASSACHUSETTS GENERAL HOSPITAL  ORGANIZATION  Massachusetts General Hospital is a major teac...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
30  e1f6655b-7020-4253-9d8c-a716b7654405                 30                                       YOGISH KUDVA        PERSON  Yogish Kudva is a medical doctor and principal...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
31  fa503b27-431d-4eea-b3c5-b52e329d02af                 31                                       SUZAN BZDICK        PERSON  Suzan Bzdick is a registered nurse and contact...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
32  f9a5fef1-9afc-4a5c-a4ad-91440147829e                 32                                     RUTH WEINSTOCK        PERSON  Ruth Weinstock is a medical doctor and princip...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
33  5ab5095d-90ea-4786-bae8-21acc3083a83                 33                                        COREY KUREK        PERSON  Corey Kurek is a contact person at Mayo Clinic...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
34  1fabd86f-660d-4ea2-bb29-ce215e356e32                 34                                     MELISSA PUTMAN        PERSON  Melissa Putman is a medical doctor and princip...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
35  a3203481-5a5f-4f53-b4e2-5746406e3645                 35                                         AMY SABEAN        PERSON  Amy Sabean is a contact person at Massachusett...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
36  fad021a2-24b4-4be2-b576-4f85fd90e446                 36                                    TYPE 1 DIABETES         EVENT  Type 1 diabetes is a chronic condition charact...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
37  4b292758-76b9-4fae-9193-6461e14504f5                 37                                          ROCHESTER           GEO  Rochester is a city in Minnesota where the May...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
38  85c34762-f717-4a2b-a7e7-c0b54df3aea2                 38                                           SYRACUSE           GEO  Syracuse is a city in New York where SUNY Upst...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
39  4083c7c9-7d70-406a-ad47-edd38692f90d                 39                                             BOSTON           GEO  Boston is a city in Massachusetts where Massac...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
40  8be220b3-6ae8-4b43-a99f-c891ad7f1a61                 40                                          MINNESOTA           GEO  Minnesota is a state in the United States wher...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
41  4f2f1709-3ffb-4d86-ac4f-f6bd759f72fb                 41                                      MASSACHUSETTS           GEO  Massachusetts is a state in the United States ...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
42  ce1f2e83-a01c-4d43-88ae-60a416ffc18b                 42                                           NEW YORK                                                                   [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
43  eef030c7-a036-4e6f-9e09-6c30555b98a6                 43                               CAPILLARY BIOMEDICAL  ORGANIZATION  Capillary Biomedical is the organization condu...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
44  d7b0344b-0195-4f0f-b348-2110fef1c2e2                 44                                   TANDEM T:SLIM X2  ORGANIZATION  Tandem t:slim X2 is an insulin pump used in th...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
45  6ea7240e-4499-4fbb-ab0e-b85511766570                 45                                      UNITED STATES           GEO  The United States is the country where the cli...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
46  15cc1d82-88da-469d-8ea5-6d8311863ccc                 46                                         START DATE         EVENT  The study is set to begin on March 7, 2024, ma...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
47  6287d663-8f61-4b38-84cc-11d8c33399a6                 47                                    COMPLETION DATE         EVENT  The study is expected to be completed by Janua...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
48  366afc6c-39d3-4d39-9f1a-a9147f79c530                 48                                       PARTICIPANTS        PERSON  Up to 300 participants aged 18-80 will be enro...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f..., errors=None)
2024-12-15 21:56:49,413 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_relationships', result=                                      id  human_readable_id                                 source  ... weight combined_degree                                      text_unit_ids
0   31dffae0-69f2-48cb-86be-18604dd5fbca                  0             TANDEM DIABETES CARE, INC.  ...    9.0              30  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
1   c08d0280-8b4f-42e3-b161-d5992f192531                  1        JAEB CENTER FOR HEALTH RESEARCH  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
2   596ae0c7-5857-4405-9ac3-a7559703c48f                  2                          ALAYNE LEHMAN  ...    8.0              29  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
3   6e153b3f-ea2c-487d-b61d-a5c74ff5d952                  3                            JOHN C REED  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
4   169b0cd0-27d9-4737-8719-5578c9f32a38                  4                          DAVIDA KRUGER  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
5   9b727388-e945-46ba-bde0-28ff8f52f9cb                  5                        BRITTANY DENNIS  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
6   477987e2-1caa-4764-9e8b-c9e02ddfd5c8                  6                     RICHARD BERGENSTAL  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
7   5f442542-9ca5-432f-9abc-047bdc843b56                  7                         SAMANTHA LANGE  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
8   c6609ca5-491f-4de2-8a6e-9e00b3455730                  8                          GRAZIA ALEPPO  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
9   3ed35160-5489-44b9-902b-9a7bb87ba46c                  9                           WYATT LARSON  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
10  cfe94da2-52a9-43c2-bbb2-18be01ec99c4                 10                              JEAN CHEN  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
11  412e9ce0-e3e8-4523-aa1f-967fa43b68ae                 11                          TINA MITCHELL  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
12  07047764-9f43-4aeb-9985-d1193c6d6df1                 12                             RAYHAN LAL  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
13  48d2dc08-7e1f-492e-983d-99df96868a68                 13                          DORI KHAKPOUR  ...    5.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
14  e1ecb61b-a04d-4e7e-a966-7fcc2b3ac54b                 14                       CAMILLA LEVISTER  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
15  1242d871-bf01-48f3-9cd9-fda8b677323b                 15                            MAYO CLINIC  ...    2.0              32  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
16  fad87ede-7796-4a0b-9494-11013c662367                 16     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
17  6cc09674-6585-435b-9eba-92066510e07f                 17     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
18  7ea0653e-6a61-4527-a718-8ea4d7f7d48e                 18     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
19  60a49f1d-a753-481c-a2ea-232effefc3d0                 19     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
20  007704bc-ccc3-41dc-a76d-8daf90b3c2be                 20     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
21  fa5e0c1a-9d05-4fd1-b5dd-2b348d0e7f78                 21     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
22  66aad45d-50c6-46e3-872a-1da66ad7e250                 22     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
23  ff57dacc-4503-4103-b77a-724e038f33df                 23     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
24  8ff834ff-14a9-4758-a378-009ad881a004                 24     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
25  ee7cbcbb-fefa-4e12-ad49-221fa7b81470                 25     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              28  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
26  3f537a3c-00a8-44fc-b35b-1f436aadb309                 26     EXTENDED WEAR INSULIN INFUSION SET  ...    8.0              29  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
27  ee326d38-77e0-452f-ae47-245ae3093c73                 27  ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ...    9.0               4  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
28  bf6db7a5-760b-4095-88fb-834cc7bdbe93                 28                            MAYO CLINIC  ...    7.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
29  138048ef-7e7e-475d-a87c-2fe75319287a                 29                            MAYO CLINIC  ...    6.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
30  c1951f1d-5c31-42e3-94cb-4dcec1a774a5                 30                            MAYO CLINIC  ...    9.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
31  878f5515-6f14-4ecf-89c3-b44694427476                 31                            MAYO CLINIC  ...    9.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
32  80721192-8eed-48a3-bde9-e9d871cf4151                 32        SUNY UPSTATE MEDICAL UNIVERSITY  ...    7.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
33  7fd1ea33-61e9-4e94-bc94-dbc504e987a6                 33        SUNY UPSTATE MEDICAL UNIVERSITY  ...    7.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
34  2178b77b-8155-4c84-80f3-cf5a54ad2995                 34        SUNY UPSTATE MEDICAL UNIVERSITY  ...    9.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
35  47b03bf6-332b-44ae-b881-f21a95f5232b                 35        SUNY UPSTATE MEDICAL UNIVERSITY  ...    1.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
36  7f21e245-6cf1-4035-876b-ab544b864f4a                 36         MASSACHUSETTS GENERAL HOSPITAL  ...    7.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
37  956fc4cb-da5a-4a51-a314-8077784cafd9                 37         MASSACHUSETTS GENERAL HOSPITAL  ...    6.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
38  b919edb3-de55-4d68-b91f-55fcd17d7963                 38         MASSACHUSETTS GENERAL HOSPITAL  ...    9.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
39  d287a59e-4581-418d-974e-d9744c3cbf79                 39         MASSACHUSETTS GENERAL HOSPITAL  ...    9.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
40  b8029f72-58c4-4338-85e4-bf5619df65cc                 40             TANDEM DIABETES CARE, INC.  ...    8.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
41  69723cad-462f-40c1-a511-c8b3354d4341                 41             TANDEM DIABETES CARE, INC.  ...    9.0               8  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
42  c85f9494-dfb4-4286-a7c3-781a96d712b9                 42                           YOGISH KUDVA  ...    8.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
43  18a06d30-73a1-4729-a3e9-a6be7542a943                 43                         RUTH WEINSTOCK  ...    8.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
44  591f752c-3879-429d-9f1b-08fd36c41ad0                 44                         MELISSA PUTMAN  ...    1.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
45  0c39c660-33fc-4dc0-8001-d64028e94088                 45                   CAPILLARY BIOMEDICAL  ...    8.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
46  29c435e1-6b07-4375-9fef-0dd4b8c2c031                 46                   CAPILLARY BIOMEDICAL  ...    9.0              11  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
47  496fee36-5ffc-4ff5-a797-d594385e3fa6                 47                   CAPILLARY BIOMEDICAL  ...    7.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
48  16177ee6-06bf-4c7d-9fdc-5aa333c3575c                 48                   CAPILLARY BIOMEDICAL  ...    6.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
49  5e40f8db-905e-4cc3-8c54-de0d9e725d18                 49                   CAPILLARY BIOMEDICAL  ...    6.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
50  15054e25-e9ca-43f8-bfbd-6309087347b8                 50                   CAPILLARY BIOMEDICAL  ...    1.0               7  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...

[51 rows x 8 columns], errors=None)
2024-12-15 21:56:49,419 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_communities', result=                                     id human_readable_id community  parent  ...                                   relationship_ids                                      text_unit_ids      period size
0  56e3110f-6d1d-490c-86eb-45a2a17fb006                 0         0      -1  ...  [138048ef-7e7e-475d-a87c-2fe75319287a, 69723ca...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    8
1  c167c039-7dc5-4ab3-bc95-c19d35f196ab                 1         1      -1  ...  [007704bc-ccc3-41dc-a76d-8daf90b3c2be, 0704776...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...  2024-12-15   24
2  404328f7-ecc8-477e-b05b-1679ef45c80d                 2         2      -1  ...  [7f21e245-6cf1-4035-876b-ab544b864f4a, 956fc4c...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    5
3  450bae1f-b4b6-4e7f-a538-be52127de1b6                 3         3      -1  ...  [0c39c660-33fc-4dc0-8001-d64028e94088, 15054e2...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...  2024-12-15    6
4  b4c3a6db-4ffb-41c4-9e6c-ca8725d41fc7                 4         4      -1  ...  [2178b77b-8155-4c84-80f3-cf5a54ad2995, 47b03bf...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    6

[5 rows x 11 columns], errors=None)
2024-12-15 21:56:49,422 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_nodes', result=                                      id  human_readable_id                                              title  community  level  degree  x  y
0   908e379b-e8d1-4dc7-be32-c967a71807a4                  0                         TANDEM DIABETES CARE, INC.          0      0       3  0  0
1   a3490882-513f-4c85-b1b0-65bcf79d6aa3                  1                    JAEB CENTER FOR HEALTH RESEARCH          1      0       1  0  0
2   aaa7ca6d-608f-4ee7-9bbf-a406980ccc29                  2                                      ALAYNE LEHMAN          0      0       2  0  0
3   b6c1ffe7-36d4-4acd-be13-2c18529effe0                  3                                        JOHN C REED          1      0       1  0  0
4   6a0357bd-1753-4eb9-9616-d98477592dbc                  4                                      DAVIDA KRUGER          1      0       1  0  0
5   b1cd393b-64cc-407e-bddf-6afeac5c3ba4                  5                                    BRITTANY DENNIS          1      0       1  0  0
6   03b2b5e0-e0fb-4d2c-8182-8c9d9c2eaa2a                  6                                 RICHARD BERGENSTAL          1      0       1  0  0
7   f1cb7990-08e3-45fe-977c-7e28c5528280                  7                                     SAMANTHA LANGE          1      0       1  0  0
8   7f6ba670-2db8-448e-b1c5-0edf2f578907                  8                                      GRAZIA ALEPPO          1      0       1  0  0
9   8ddfb07e-7b56-45db-8f49-971fc7d5d2b4                  9                                       WYATT LARSON          1      0       1  0  0
10  09dd480a-3dd8-499b-9390-9f287bf5e66f                 10                                          JEAN CHEN          1      0       1  0  0
11  18139ae3-a441-48e1-b6c9-fc1be7282717                 11                                      TINA MITCHELL          1      0       1  0  0
12  0c766ec0-0059-4e3c-b1b4-42b637061769                 12                                         RAYHAN LAL          1      0       1  0  0
13  157d2eaa-7726-4f18-8435-cf93e1686f7b                 13                                      DORI KHAKPOUR          1      0       1  0  0
14  32079101-61a5-4cbd-9161-e8ed225c52e9                 14                                   CAMILLA LEVISTER          1      0       1  0  0
15  7e874f82-f87c-48e4-a1ab-2e20497e8a81                 15                                        MAYO CLINIC          0      0       5  0  0
16  68d0c128-4506-4e70-b6bb-260ef7460b75                 16                 EXTENDED WEAR INSULIN INFUSION SET          1      0      27  0  0
17  bbbe945a-db9e-4cb6-8325-c4cfa11b27be                 17                           HENRY FORD HEALTH SYSTEM          1      0       1  0  0
18  b9f31ada-5ca3-4b46-8870-d8fd94edf05c                 18                HOAG MEMORIAL HOSPITAL PRESBYTERIAN          1      0       1  0  0
19  6bb5b0d1-c24c-4119-bce1-5be518c99817                 19  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...          1      0       1  0  0
20  1e6edc99-41d4-49d6-a619-49c3a31305aa                 20                               BARBARA DAVIS CENTER          1      0       1  0  0
21  a60f7332-09fa-4228-8b59-4ba3c543d993                 21                            NORTHWESTERN UNIVERSITY          1      0       1  0  0
22  dd4917b0-af46-4be7-af68-dc31216f003e                 22                   TEXAS DIABETES AND ENDOCRINOLOGY          1      0       1  0  0
23  2c511ac6-2410-422c-972c-3fc9afbdbf05                 23                   RAINIER CLINICAL RESEARCH CENTER          1      0       1  0  0
24  5110c732-134e-4145-a804-9eb4da7d4d29                 24                                STANFORD UNIVERSITY          1      0       1  0  0
25  1ca72b77-8251-4cca-8788-a4d62471fc3d                 25                           UNIVERSITY OF WASHINGTON          1      0       1  0  0
26  4c14cfcd-816d-4b02-9751-3296cc5989be                 26              ICAHN SCHOOL OF MEDICINE AT MT. SINAI          4      0       2  0  0
27  9b2de6c0-256c-4bed-a45f-032cdfa47a3a                 27                       ENDOCRINE RESEARCH SOLUTIONS          1      0       1  0  0
28  0d8bde39-c8ab-48a4-8da6-a165ca2ea71d                 28                    SUNY UPSTATE MEDICAL UNIVERSITY          4      0       4  0  0
29  e5a2b981-d8d3-4e2b-bd80-0eb662af2342                 29                     MASSACHUSETTS GENERAL HOSPITAL          2      0       4  0  0
30  e1f6655b-7020-4253-9d8c-a716b7654405                 30                                       YOGISH KUDVA          0      0       2  0  0
31  fa503b27-431d-4eea-b3c5-b52e329d02af                 31                                       SUZAN BZDICK          4      0       1  0  0
32  f9a5fef1-9afc-4a5c-a4ad-91440147829e                 32                                     RUTH WEINSTOCK          4      0       2  0  0
33  5ab5095d-90ea-4786-bae8-21acc3083a83                 33                                        COREY KUREK          0      0       1  0  0
34  1fabd86f-660d-4ea2-bb29-ce215e356e32                 34                                     MELISSA PUTMAN          2      0       2  0  0
35  a3203481-5a5f-4f53-b4e2-5746406e3645                 35                                         AMY SABEAN          2      0       1  0  0
36  fad021a2-24b4-4be2-b576-4f85fd90e446                 36                                    TYPE 1 DIABETES          0      0       5  0  0
37  4b292758-76b9-4fae-9193-6461e14504f5                 37                                          ROCHESTER          0      0       1  0  0
38  85c34762-f717-4a2b-a7e7-c0b54df3aea2                 38                                           SYRACUSE          4      0       1  0  0
39  4083c7c9-7d70-406a-ad47-edd38692f90d                 39                                             BOSTON          2      0       1  0  0
40  8be220b3-6ae8-4b43-a99f-c891ad7f1a61                 40                                          MINNESOTA          0      0       1  0  0
41  4f2f1709-3ffb-4d86-ac4f-f6bd759f72fb                 41                                      MASSACHUSETTS          2      0       1  0  0
42  ce1f2e83-a01c-4d43-88ae-60a416ffc18b                 42                                           NEW YORK          4      0       2  0  0
43  eef030c7-a036-4e6f-9e09-6c30555b98a6                 43                               CAPILLARY BIOMEDICAL          3      0       6  0  0
44  d7b0344b-0195-4f0f-b348-2110fef1c2e2                 44                                   TANDEM T:SLIM X2          3      0       1  0  0
45  6ea7240e-4499-4fbb-ab0e-b85511766570                 45                                      UNITED STATES          3      0       1  0  0
46  15cc1d82-88da-469d-8ea5-6d8311863ccc                 46                                         START DATE          3      0       1  0  0
47  6287d663-8f61-4b38-84cc-11d8c33399a6                 47                                    COMPLETION DATE          3      0       1  0  0
48  366afc6c-39d3-4d39-9f1a-a9147f79c530                 48                                       PARTICIPANTS          3      0       1  0  0, errors=None)
2024-12-15 21:56:49,426 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_text_units', result=                                                  id  human_readable_id  ...                                         entity_ids                                   relationship_ids
0  07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938ab...                  1  ...  [908e379b-e8d1-4dc7-be32-c967a71807a4, a349088...  [31dffae0-69f2-48cb-86be-18604dd5fbca, c08d028...
1  50fcd19011dc02899d75146662bd0110ec7409cbfdb069...                  2  ...  [908e379b-e8d1-4dc7-be32-c967a71807a4, aaa7ca6...  [ee326d38-77e0-452f-ae47-245ae3093c73, bf6db7a...
2  616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686fd...                  3  ...  [fad021a2-24b4-4be2-b576-4f85fd90e446, eef030c...  [0c39c660-33fc-4dc0-8001-d64028e94088, 29c435e...

[3 rows x 7 columns], errors=None)
2024-12-15 21:56:49,432 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='create_final_community_reports', result=                                 id  human_readable_id  community  parent  ...                                           findings                                  full_content_json      period size
0  8bd2fd17dcc84ed2a0cf86c69124ad40                  0          0      -1  ...  [{'explanation': 'Mayo Clinic is a leading med...  {\n    "title": "Mayo Clinic and Tandem Diabet...  2024-12-15    8
1  6ed78d801b0c48feb0ae8506279c3941                  1          1      -1  ...  [{'explanation': 'The Extended Wear Insulin In...  {\n    "title": "Extended Wear Insulin Infusio...  2024-12-15   24
2  27e59eec28ae45a78d6ca474cdbdaf29                  2          2      -1  ...  [{'explanation': 'Massachusetts General Hospit...  {\n    "title": "Massachusetts General Hospita...  2024-12-15    5
3  430f19d6c5b5423b9b083d84d0e516fb                  3          3      -1  ...  [{'explanation': 'Capillary Biomedical is the ...  {\n    "title": "Capillary Biomedical Clinical...  2024-12-15    6
4  ebd8f76320cf45b2b4bb5dbbbed5ccb9                  4          4      -1  ...  [{'explanation': 'Dr. Ruth Weinstock is a prin...  {\n    "title": "SUNY Upstate Medical Universi...  2024-12-15    6

[5 rows x 14 columns], errors=None)
2024-12-15 21:56:49,432 - __main__ - INFO - Workflow completed successfully: PipelineRunResult(workflow='generate_text_embeddings', result=Empty DataFrame
Columns: []
Index: [], errors=None)
